The physiologicalcosts associated with poor sleep are well documented, but what about all of the ways in which insufficient rest stands between us and our life goals?

A new study conducted by researchers over at HealthySleep set out to determine how many ambitions are achieved and abandoned as a direct consequence of sleep quality.

With a recruitment comprised of more than 1,000 participants the team successfully established a correlation between slumber and the achievement of life goals.

Before the researchers began tracking the respondents, each was asked to complete a questionnaire in regards to their most pressing long-term objectives. The top results are as follows:

On balance, good sleepers were about twice as likely to receive career success compared to poor sleepers in addition to achieving their goals 30% more often. Some objectives, like securing a raise or a promotion, were more frequently cited than others (72% vs. 68% respectively.)

Is there anything a good nights sleep cant do? Getting proper rest night after night can contribute to improved heart health, reduced stress, increased alertness, and improved memory, among many other wellness-related benefits. Given that satisfactory snoozing can be the blueprint for a sharper mind and a healthier body, we were curious about the link between rest and success and whether there was one to be found, the authors write in the paper.

Generally speaking, medical professionals recommend adults between the ages of 26 and 64 receive about nine hours of sleep per night. This value is more accurately determined by genetics, preexisting conditions, and even weight. Given the volume of variables that depict quality rest the researchers decided to rely on markers that were relative to the individuals involved in their particular analysis.

Five hundred and ninety-one respondents identified as female, 414 respondents identified as male, and four respondents did not identify as male or female. The participants ranged in age from 18 to 75 with a median age of approximately 37.

Twenty-seven percent of the study pool received five hours of sleep or less a night, 26% received an average of six hours and 32 minutes of sleep a night and the largest portion of the recruitment (47%) managed to score an average of seven hours and 10 minutes of sleep a night. The first and last demographics served as the poor and adequate sleep control spectrum.

Poor sleep seemed to reliably contribute to procrastination. Eighty-percent of the good sleepers and 75% of the average sleepers reported putting a lot of effort into their goals compared to the 68% of bad sleepers who could say the same.

Good sleepers were both better at tracking the progress of their goals and the more likely group to secure them.

Good sleepers reported achieving an average of 68% of their potential goals, compared to bad sleepers 58%.At every echelon 50% or more, 75% or more, and 90% or more a higher percentage of good sleepers said they could reach the respective percentage of their goals, the authors conclude.Respondents who fell into the good sleeper category were better equipped to succeed in every way.They achieved more goals, put more effort into where they wanted to be, were better organized in their goal-setting approach, procrastinated less, and were more likely to adopt a positive mindset regarding their own abilities and strengths.

Here are the most occasioned goals achieved by those who habitually received quality rest:

Originally posted here:
Study: 72% of people that sleep this many hours a night secure raises - Ladders

Recommendation and review posted by Bethany Smith

What if I told you that in Australia, a mouselike marsupial called antechinus breeds so manically during its three-week mating season that the males bleed internally and go blind, until every male lies dead? And what if I told you that this isnt the reason the species is facing an existential threat?

Reporting today in the journal Frontiers in Physiology, biologists from University of New England in Australia and the Norwegian University of Science and Technology present troubling evidence that antechinus might be ill-prepared for a warmer world. The researchers set out to look at something called phenotypic plasticity in the yellow-footed antechinus, one of the creatures 15 known species. Think of your phenotype as your bodys hardware, or physiology: your height and skin color and metabolism. This is in part coded by your genotype, the genetic software that powers the hardware. Phenotypic plasticity is the ability of a species to respond to environmental stressorslike temperature swingsby altering their physiology without mucking with all the underlying genetics.

For the antechinus, the researchers were interested in the plasticity of its metabolism. This is highly influenced by temperature: An adult antechinus metabolism shifts to expend less energy when its cold during the winter and there isnt much insect prey for it to hunt. When its warm, an antechinus can afford to expend a lot of energy because prey is plentiful.

The researchers, though, were more interested in how temperature affects antechinus babiesthat is, how being raised in cold or warm environments might affect how their metabolism works once they become adults. So they reared two groups of babies, one in colder temperatures and one in warmer temperatures. They then flipped the thermostat, exposing the individuals reared in the cold to warm temperatures and the warm-reared ones to the cold.

As the researchers expected, when the temperature switched from warm to cold the animals decreased their activity levels, which the scientists were recording using infrared sensors that logged movements. This is perfectly natural for wild animals, since in winter they have fewer insects to hunt and need to conserve their energy to keep from starving. In fact, in the dead of winter, antechinus can slip into a state called torpor, drastically lowering their body temperature and metabolic rates.

In the lab, the researchers also found that when turning up the heat on animals that had been reared in the cold, the animals increased their activity levels, just like they would in the wild as warmer spring temperatures bring more insects to hunt.

So far so gooduntil the researchers also looked at the metabolic rates, instead of just the activity levels, of the animals as they experienced temperature shifts. A metabolic rate is the measure of how much energy the animal needs to maintain function at rest. For a mammal like antechinus, that rate can change significantly when outdoor temperatures go up or down. Unlike a reptile, a mammal like antechinus has to constantly maintain its own body temperature, either spending energy to cool or warm itself.

This time, the researchers found that when the antechinus raised in the warm group shifted to the cold, they increased their metabolic rate only slightly. But those raised in the cold group that shifted to the warmth decreased their metabolic rate significantly. The discrepancy suggests that the babies brought up in cold conditions have more plastic phenotypes when it comes to adjusting to temperature changes.

So we hypothesize that perhaps these results reveal that antechinus that are raised in cold conditions have more flexibility in their physiology than those that are raised in warm conditions, says physiological ecologist Clare Stawski of University of New England in Australia and the Norwegian University of Science and Technology, lead author on the new paper. Which might show you that in the future when it's much warmer, and more consistently warm, that the antechinus might not be as flexible to changes in the climate.

Read more here:
This Marsupial Dies After Marathon Mating. Now It's Got Bigger Worries - WIRED

Recommendation and review posted by Bethany Smith

By Paul Biegler

A German study has found that pregnant women who use parabens chemicals widely used as preservatives in cosmetics, foods and drugs could increase the risk of their children being overweight.

The study, published in Nature Communications, suggests weight gain may be caused by epigenetic changes that limit the ability to feel full after eating.

The team, led by Irina Lehmann from the Berlin Institute of Health, analysed 629 mums and their babies who took part in the LINA study (Lifestyle and Environmental Factors and their Influence on Newborns Allergy) between 2006 and 2008.

LINA tested whether pollutants such as tobacco smoke could affect babies. Crucially, it also measured the mothers exposure to parabens.

Parabens are antibacterials used in cosmetics such as moisturisers, shampoos and shaving cream. The agents are also found in baked goods, jams and other foods.

In 1995 parabens were put on the US Food and Drug Administrations Generally Recognised as Safe (GRAS) list but, more recently, questions have been raised about a link to breast cancer.

The chemicals are classed as endocrine disruptors and can mimic the action of the female hormone oestrogen, potentially relevant for hormone-sensitive cancers.

Lehmanns team found women who used leave on (as opposed to rinse off) skin products containing parabens had urine levels up to three times higher than women who used paraben-free products.

Then they went on to look at how the childrens weight tracked.

Between the ages of two and eight, the team found, kids of mums exposed to higher levels of parabens in pregnancy had more than double the odds of being overweight at any point.

The findings came, however, with riders.

The effect was only seen with two out of the five parabens studied, known as iso-butyl paraben (iBuP) and n-butyl paraben (nBuP). And when the researchers did a further statistical breakdown the weight gains were most pronounced in girls.

Intrigued by the result, Lehmanns group devised a mouse study to see what might be causing it.

They injected nBuP under the skin of pregnant mice, which gave them urine levels of the paraben comparable to the high exposure human mums. Then they waited to see what happened to the mouse bubs.

Quite a bit, it turned out.

Pups of paraben-treated mothers were fatter at all points during the observation period of 12 weeks. But, again, the effect was only seen in females.

Wondering if paraben might be working directly on fat cells, the team added nBuP to human and mouse fat cells in culture plates in the lab. But there was no effect on the growth of the fat cells.

Which left the live prospect that paraben could be affecting appetite itself.

The team homed in on a structure in the mouse brain called the hypothalamus. Its an area rich in receptors for leptin, a hormone that goes up after eating to tell the brain youre full.

It seemed they had found their smoking gun.

For leptin to deliver the Im full message it has to turn on production of a peptide called pro-opiomelanocortin (POMC) in the hypothalamus. If POMC isnt there you dont feel full and you get fat. The paraben babies, it turned out, had less POMC, ate more and were heavier.

When the team did a deep dive into the genetics, they found an epigenetic "gene switch" called methylation was the likely culprit. How did they know for sure? When the team blocked methylation in the baby mice whose mums got paraben, it put a lid on the weight gain.

With our mouse experiment, we demonstrated that... foetal development seems to be a sensitive time window for nBuP exposure with respect to body weight regulation, they conclude.

There are, however, reasons to take the findings cautiously.

In previous studies, it was found that mouse physiology may not be identical to humans when it comes to paraben metabolism, says Alex Polyakov, Consultant Obstetrician and Gynaecologist at the Royal Women's Hospital in Melbourne, who was not involved in the study.

Therefore the mechanism of paraben effect on the risk of obesity in humans may be different, he says.

And questions remain unanswered: for example, why females are affected disproportionately. The authors speculate it may be linked to the female hormone oestrogen.

Nonetheless, Polyakov sees reason to tread carefully.

At this time, it would be advisable for pregnant women to avoid cosmetic compounds that contain paraben. Complete avoidance of paraben is not possible as its use is so widespread, but avoiding non-essential exposure seems like a prudent and easily achievable goal, he says.

Read more from the original source:
Parabens linked to weight gain in childhood - Cosmos

Recommendation and review posted by Bethany Smith

The 2020 shortlist for the coveted #21toWatch Awards includes some of the most daring entrepreneurs and innovations from our region.

Out of hundreds of entries received, 246 qualified candidates made it onto a longlist, which has now been whittled down to a shortlist of 56, featuring a dynamic mix of people, companies and things.

Winners of the awards, run by Burwell-based Cofinitive and supported by the Cambridge Independent, will be unveiled at an event at Arm on March 5.

The shortlist of people includes:

Entrepreneur and Cofinitive founder Faye Holland said: We are really delighted to see an equal number of women to men featuring on the People shortlist this year. In key sectors where female entrepreneurs, founders and leaders are few and far between, this really is most encouraging.

Its also been exciting to see the wide range of industries represented on this years list. Theres been a huge shift from last year with ICT now making up 33 per cent of the shortlist, although there are a number of strong contenders in the biotech and medtech sectors too.

We also have a stronger representation from cleantech and agritech as well as increased diversity around retail, industrial and more people-based solutions. All this is a clear reminder of how amazingly diverse our region is, and the huge opportunity for convergence and agglomeration we can offer these businesses.

The shortlisted companies include:

And some Cambridge companies on the things shortlist include:

The #21toWatch shortlist is independently judged by four leading experts across a range of disciplines.

For 2020, the judges are Isabel Fox, of Luminous Ventures, Tim Robinson, of Tech East, Siddhi Trivedi, of Entrepreneur, and Bruno Cotta, of the Cambridge Judge Business School Entrepreneurship Centre, who will all assess the candidates based on five criteria: innovation, challenge, influence, viability and memorability.

Tim said: What impressed me most is that so many of the shortlist are people and companies addressing major real-world challenges in climate change, ethical AI, security, precision medicine and more.

Arm and HSBC have recently joined the #21toWatch campaign as sponsors in readiness for the awards event. Itll be one to watch in its own right.

The shortlist

People

Companies

Things

Meet the judges

Bruno Cotta is executive director at Cambridge Judge Business Schools Entrepreneurship Centre. He has more than 20 years of leadership and management experience working with public, private and third sector organisations, and has led initiatives to inform and shape world-class university strategic plans, international partnerships and innovation ecosystems, including founding the Enterprise Lab at Imperial College London to support the next generation of innovators and entrepreneurs;

Isabel Fox is a mother, wellness coach, biohacker, Peloton enthusiast and horse lover. She also happens to be one of just a handful of female general partners in the UK, at Luminous Ventures, with a $30million fund and a portfolio of groundbreaking founders who are daring to disrupt the status quo;

Tim Robinson is the first chief operating officer of Tech East, the leading voice of the digital tech community in the East of England. He spent 14 years with the Royal Institution of Chartered Surveyors (RICS) in London where he created a product technology division in 2007 and ran the information, data and technology business from 2010-14.In 2014, Tim founded his own marketing strategy consultancy in Suffolk, specialising in the technology sector.

Siddhi Trivedi is a multi-award-winning disruptor in technology with 30 years of business innovation. Her projects have featured in TechCrunch, Disrupt Berlin, Novo Nordisk Innovation Awards and many more. She is continuously searching for pioneeringideas that will change the world and features them on the global TEDx platform as curator and licence holder of TEDxLeicester.

What does it mean to get on the shortlist?

Kay McGuinness, of ANB Sensors, was one of the top 21 in 2019.

She says: Being on the Cofinitive One to Watch Top 21 list in 2019 has been great for us. We were in the process of going through a funding round, and the recognition gave our potential investors greater confidence in us as a company and the products we were developing. As we go commercial this year, the award lends greater initial credibility to our offering as a new player on the market.

But even those on the longlist neednt be disappointed if they dont make it onto the shortlist.

Richard Hobson, Herdsy, appeared on the 2019 longlist.

He says: Just being on the longlist raised our profile beyond our wildest expectations. To be highlighted amongst Cambridges brightest and best put us on the radar of several high-profile customers and investors, and lead to our company being profiled in the Sunday Times, giving us national exposure.

Being on lists doesnt usually make that much difference - but getting on this one will change your company direction forever. It was a game-changer for our small company.

People have actually heard of us now, and customers and investors Google us and rate us among the best globally as a direct result. How many lists can you say that about?

This year, Herdsy has been shortlisted in the #21toWatch Things shortlist.

Read more

#21toWatch in 2020 - nine trailblazers on Cofinitives longlist revealed

Watch the highlights and see the pictures from the Cambridge Independent Science and Technology Awards 2019

Stemnovate offers unique multi-organ drug screening on reprogrammed human cells

Agile Analog awarded Innovate UK funding towards 1m project

Cambridge technology that locks CO2 into rock will halt climate change

Six-minute lithium battery recharge for phones and cars on way

Alkane data puts Intellegens lubricants in R&D driving seat

OKRA founder calls for open data to drive up cancer care

Riverlane building operating system for quantum computers

Academy Award winning pedigree of AudioTelligence, the Cambridge start-up thats raised 3.1m

Cambridges FlexEnable folds display borders for bezel-less screen

Cambridge firm Sano Genetics bakes ethics into its genomic platform

Go here to read the rest:
#21toWatch shortlist of people, companies and things revealed - Cambridge Independent

Recommendation and review posted by Bethany Smith

With so many options on the market, how do you know you are making the right decision when choosing an eye cream?

As a makeup artist, Brandie Price says she relies heavily on the tools she has in her kit to create the best possible outcome for clients whether that be a television show, photo shoot, or speaking engagement. Each set of eyes is different, and each persons goals are different, so a variety of tools are needed to achieve a variety of goals on hand. Here are Brandies TOP 4 favorite eye creams:

Arbonne-RE9 Advanced Lifting and Contouring Eye CreamThe RE9 eye cream uses cassava, which initiates the appearance of a nearly instant eye lift. Additional ingredients like Peony to deepen the conditioning and Algae to support the extracellular matrix help to tone and contour your delicate eye area. I use this this eye cream on clients that have a touch of droopiness above the eye area. A few minutes of waiting gives a more smooth canvas for eye shadow application. This eye cream can be used all 360 degrees around the eye.

Artistry-Supreme LX Eye CreamThe Supreme LX line by Artistry uses 2 of the most expensive ingredients to resynchronize our skins 24 hour biorhythms. If you dont get 8 hours of sleep, you decrease the possibility of proper cellular structure regeneration. The Cardiolipin, 24K gold, and gardenia grand flora stem cell extracts encourage your skins natural biorhythms to increase that cellular generation regardless of the time you spend sleeping. This eye cream has an instant reduction in creepiness and droopiness and long term effects similar to that of Blepharoplasty. I use this eye cream with clients that have signs of crepiness or crepiness that runs in their family, and long term clients that want to see lasting benefits without surgery.

Monat-30 Second MiracleThe Monat 30 Second Miracle is just that. Within 30 seconds of application you literally feel and start to see all of the puffiness and discoloration disappear. This effect is no trick pony, the results last up to 12 hours. I use this for on the spot reductions of puffiness for on camera clients, photo shoots, and speaking engagements. This is a great addition to your daily eye cream and skin care regimen. It does not lead to a lasting result, think of it more as a booster. Its versatile in that it can also be used in creases along the forehead, laugh lines, and any other location you have developed a fine line.

Rodan & Fields-Redefine Multifunction Eye CreamThe R&F Redefine Eye Cream uses Glycerine to penetrate the skins surface and restore a healthy and hydrated moisture table in the delicate skin around the eye. A proprietary blend of peptides help to reduce fine lines and wrinkles over time. Hydration helps your skin cells look more plump like grapes and less shriveled like a raisin. I use this eye cream to instantly boost hydration. Many of my clients suffer from dehydration while traveling and are coming right into a photo shoot or television segment with tired, dry eyes and this is a wonderful solution.

Visit http://www.brandiepriceimage.com for Giveaway details. There will be 4 lucky winners, who will each win one of the featured eye creams in Brandies list of favorites!

Brandie Price is an Award-Winning Makeup Artist and Celebrity Personal Brand Expert. You can find her at http://www.brandiepriceimage.com or on Social: Instagram @brandiepriceimage or Brandie Price on Facebook.

See original here:
Makeup artist shares her FOUR favorite eye creams that you CANNOT buy in a store - WISHTV.com

Recommendation and review posted by Bethany Smith

In the rush to get ready for work or kick back in front of Netflix at night, its easy to forget to look after your skin. But as winter bites, its time to step up your skincare routine, or risk developing dry, flaky and uncomfortable skin.

Of course, everyones skin is different and one mans rich moisturiser is anothers potential acne, but from vitamin-infused face washes, to SPF and face oil, weve got something to keep everyones skin looking its best.

(Image credit: Mr Porter)

The best mist to keep your skin juicy

+Great for freshening up+Contains hyaluronic acid

If you work in a highly heated or air-conditioned office and you have dry or dehydrated skin, youll need a little something to keep you skin happy. Face mists are brilliant because you can spritz and go without any mess or a mirror. Dr Barbara Sturms hydrating face mist is infused with hyaluronic acid which is great for hydrating dry and dehydrated skin, as well as purslane extract to nourish skin while protecting cells from free radicals. If thats not enough, its also packed with detoxifying extracts such as lemon, aloe vera and broccoli to minimise the effects of pollution and stress.

(Image credit: Mr Porter)

The best SPF to block harmful rays

+SPF 50+Great price

Whether youre whooshing down ski slopes or going for a wintery walk, an SPF is essential to block harmful rays and to keep you looking younger for longer. Jaxon Lanes Rain or Shine moisturising sunscreen is designed to shield your skin from UVA and UBV rays and offers SPF 50+ protection. Lightweight and non-greasy, it's infused with vitamin E, hyaluronic acid, green tea, liquorice root and ginseng so it not only protects but moisturises and enlivens your skin too.

(Image credit: Mr Porter)

Best deep-cleaning cleanser

+Great price point+Deep cleaning power of charcoal+Suitable for all face types

Washing your face in the winter isnt always the most pleasurable experience if your bathroom is cold. But a nice face wash can help. Clinque for Mens charcoal face wash harnesses the deep-cleaning power of charcoal, which is great for all skin types, especially those with slightly greasy complexions. The detoxifying gel formula is designed to work into a foam and draw out dirt, oil and impurities but isnt drying. Like all Clinque products its non-scented, which makes it a winner for sensitive skin too.

(Image credit: Mr Porter)

Best for the winter sports

+Hydrating, soothing solution+Designed to protect

Gliding down ski slopes and playing in powdery snow may fun, but a dry, red face blasted by the wind and sun isnt, so you definitely dont want to go off-piste with your skincare. If youre going skiing or are spending lots of time in the great but freezing outdoors, try Dr Barbara Sturms aptly-named Ski Cream. Its definitely not cheap, but it does promise a lot, acting as a protective shield against wind and extreme climates. Suitable for all skin types, the cream contains balloon vine, blackcurrant oil and purslane to soothe skin and reduce redness, while shea butter and jojoba oil lock in moisture.

(Image credit: Mr Porter)

The best moisturising serum

+Natural ingredients+Lighter than creams+Beautiful packaging

-Empty List

Aesop may be a favourite on Instagram thanks to its seriously stylish packaging, but the skincare brands parsley seed range packs a botanical punch. The anti-oxidant serum is a lighter alternative to creams and can be used daily after cleaning. The aloe-vera based formula contains other botanical extracts, such as parsley and grape seed oils to soften and moisturise. Plus, its designed to give skin strength and flight of environmental aggressors, which is ideal for winter months and city living alike. Its a stylish skincare solution that wont break the bank.

(Image credit: Mr Porter)

Best for brightening the complexion

+Exfoliates and brightens in one+Can help with pigmentation problems+A good multitasker

You remember to eat your five a day, but vitamin-infused skincare is great for keeping your face looking good too. 111SKINs vitamin C brightening cleanser is a great multitasker, tackling lots of issues in the time it takes to wash your face. A great addition to your morning routine during the winter months, its packed with radiance-boosting vitamin C to help reduce hyper-pigmentation, age spots and uneven skin tone. The exfoliating formula promises leaves your complexion looking clear, even and illuminated, which isnt bad for a quick scrub. Its not cheap, but it might just work miracles.

(Image credit: Mr Porter)

The best anti-ageing moisturiser

+High tech formula+Free from parabens, sulphates and gluten+For all skin types

Not all moisturisers are created equal. Sure, some are a couple of quid and do a little to keep your skin soft, but others, like MALIN + GOETZ advanced renewal moisturiser do much more. Of course, all this comes at a cost and the stylish brands high-tech daily moisturiser is pretty expensive. But its blended with antioxidant-rich meadowfoam seed oil and a combination of sugar molecules, barley and sodium hyaluronate to reduce the appearance of fine lines and wrinkles. Meanwhile, linseed extract, which is rich in Omega-3 fatty acids, trap water molecules to make your skin look healthier and plumper, and apple stem cell protects against harsh environments, which is ideal in winter.

(Image credit: Mr Porter)

Best moisturiser for dry and sensitive skin

+Hypoallergenic and gentle+Good for everyday use+Also has some anti-ageing benefits

Everyones skin needs a little extra TLC in the colder months, but those with dry and sensitive complexions can really suffer as chilly winds and harsh heating take their toll. But, PERRICONE MDs hypoallergenic nourishing moisturiser can help. Designed for specifically for dry and sensitive skin, its hypoallergenic and paraben-free, and harnesses the antioxidant properties of vitamin E along with with nourishing olive polyphenols. Gentle enough for everyday use, the brand also claims its good for keeping fine lines and wrinkles at bay.

(Image credit: Mr Porter)

Best lip balm for outdoors

+SPF 30+Water-resistant+Contains natural oils

If youre hitting the slopes or spend a lot of time outside, its important to protect your lips from the elements to avoid them becoming chapped, or sunburnt if theres snow around. Shiseidos Suncare UV Lip Color Splash SPF30 may be a bit of a mouthful, but it will protect your lips admirably. The balm is infused with natural oils to lock in moisture, as well as that all-important SPF protection. It costs considerably more than the likes of Carmex, but its water resistant, you wont need to apply it too often.

(Image credit: Mr Porter)

Best scrub for exfoliating

+Soothing and brightening+Uses sand for exfoliation

-Empty List

Regular exfoliation helps keeps skin healthy and clear, and when done before shaving can reduce bumps and irritation. While its important all year round, its great for preventing patches of dry skin building up and blocking pores in the winter and can make your complexion look brighter. Anthonys facial scrub is formulated with boro boro sand to remove dead cells, as well as soothing aloe vera, algae and chamomile. Antioxidant-rich Vitamin C is also included to protect from environmental stressors and brighten the complexion. The scrub is a handy multitasker and offers a lot of bang for its buck.

(Image credit: Mr Porter)

The best luxury hand cream

+Trendy fragrance+Easily absorbed formula+Luxe packaging

Its not just your face you need to look after in the cold and a hand cream is essential. Byredos Tulipmania hand cream is one of the trendiest options out there. Named after the infamous "tulip mania" period during the Dutch Golden Age when the flowers were in high demand, the cream is lightly fragranced with notes of Freesia and Blond Woods. Byredos hand cream is formulated with moisturising ingredients and has a gel-like consistency that's quick-drying and absorbent, which is a big selling point for busy men and women alike.

Liked this?

Read more:
Winter skincare routine: products to protect your face from cold weather - T3

Recommendation and review posted by Bethany Smith

Photo: Yulia Gorbachenko

BEST ACNE-REDUCING FACIALRejuran Healer+ Laser Peel$737 for 60 minutes, Priv ClinicAt the heart of this facial is polynucleotide, a biopolymer molecule highly compatible with the human body. Delivered into the skin via a series of micro injections, it reportedly helps repair damaged skin cells, boost collagen synthesis, reduce sebum production and even out the skins moisture-oil balance. The miniscule punctures in the skin also trigger its natural wound-healing response, boosting cellular turnover. Some light swelling may appear post-treatment, but it goes away within 24 hours. Meanwhile, skin is visibly suppler, and looks smoother and healthier.

BEST ANTI-AGEING FACIALInstant Youth ProgrammeFrom $260 for 75 minutes, EstheClinicBehold the ultimate helping hand to counter the signs of mature skin. Each treatment is uniquely tailored to your specific skin type and needs, with subsequent sessions building on and enhancing the effects of prior treatments to maximise collagen production for firmer skin. By using the latest in aesthetic technology alongside EstheClinics specially selected cosmeceutical products, the signs of ageing are thus tackled from the inside out, with effects continuing to last up to four months after completing the programme.

BEST ANTI-BLEMISH FACIALTetra+ $398 per session, The Aesthetics Medical ClinicThis four-in-one treatment features a symphony of lasers with varying wavelengths to tackle multiple issues in just one sitting. A pigment wavelength breaks down melanin clusters to improve discoloration; a custom fractional laser refines texture; a superficial wavelength zaps clogged pores clean; and a long-pulse wavelength stimulates collagen production. Expect minimal to no downtimeand a smoother complexion in no time at all.

BEST BRIGHTENING FACIALRejuvenation Laser and Stem Cell Infusion$1,888 for five sessions, The Aesthetics Medical ClinicCombining two laser machinesQ Switch and yellow laserthat work in tandem to give you radiant, glowy skin, this also removes dirt, dead skin cells, oil and superficial hair, so skin is not only brightened, but also clearer and cleaner. The laser also helps to regulate oil production and reduce pigmentation, while the potent 80percent stem cell-derived serum delivers proteins, growth factors and cytokines intoskin to help boost regeneration and repair.

BEST CLEANSING FACIALJet Set$129 for 30 minutes, EPIONIdeal as a maintenance facial for time-strapped individuals, this express purifying solution rejuvenates weary skin in 30 minutes. A highpressure aqua jet peel gently sweeps away any build-up of dry and dead skin, before an ultrasonic deep cleanse purges pores of dirt, sebum and impurities. Jet technology is then used to infuse skin with potent actives with intense hydrating and brightening benefits.

Related article:BAZAAR Spa Awards 2020: Best Face Therapies To Transform And Pamper Your Skin

BEST DETOXIFYING FACIALVitamin C Infusion$288 for 45 minutes, Simply AestheticsBid adieu to skin woes such as open pores, blemishes, pigmentation and dullness with a super-potent dose of medical-grade vitamin C, which smooths and revitalises the skin. Besides getting rid of pore-clogging impurities that can make the skin appear dull or lacklustre, the facial also stimulates the dermal cells to actively produce collagen in order to regain that plump, fresh-faced radiance.

BEST EXPRESS FACIALIDS Electro Infusion (IEI)$280 for 45 minutes, IDS AestheticsGreat as a lunchtime facial, this uses a combination of electronic-magnetic pulses and LED light to brighten and firm skin. Designed to tackle various skin conditionspigmentation, fine lines, wrinkles, dryness, dullnessthis quickie facial is deemed a universal beauty enhancer and works its magic in less than an hour.

BEST EYE LIFT TREATMENTSygmaLift Eyes$670 for 60 minutes, Clifford AestheticsWhether its eyebags or dark circles that no concealer can hide, the root causes of your undereye issues are sussed out with a consultation in order to tailor an effective treatment. SygmaLift therapy, which utilises high-intensity focused ultrasound technology, is then applied to the under-eye area to contract the connective tissues deep within to tighten and smooth skin. The end resulta marked improvement in the appearance of under-eye bags, sagginess, discoloration and linestakes years off your face!

BEST HYDRATING FACIALHydraFacial$250 for 35 minutes, Dr Kevin Chua Medical & AestheticsThis all-in-one treatment starts off with a deep cleanse, and an exfoliating cocktail of salicylic and glycolic acids to break up pore-clogging impurities, allowing the HydraPeel Tip to essentially vacuum out sebum, product build-up, blackheads and dirt, before infusing skin with intensive serums to replenish hydration levels and provide antioxidant protection.

BEST LIFTING & FIRMING FACIALThermage FLX$5,350 for 90 minutes, Priv ClinicWant to reduce the look of fine lines, wrinkles, sagging skin and other signs of ageing, or simply delay their dreaded appearance? Promising just that is the Thermage FLX, which uses radio frequency to stimulate cell regeneration and collagen production. This newgen treatment is optimised for improved comfort and more controlled delivery, and the results from one session is said to last for months.

BEST PORE-REFINING FACIAL3D Deep Pore Cleansing Facial$588 for 90 minutes, Aesthetics Central ClinicFlawless skin can now be had with this signature treatment that utilises a patented device called 50 Micron Jet Technology, where high-pressure micro-jets of water gently push out the sebum and impurities trapped in pores. As the pores are being cleaned out, the machine delivers a serum, designed to lift and tighten skin while encouraging microcirculation, deep into the skin.

BEST REJUVENATING FACIALPicoWay RESOLVE $650 for 30 minutes, Dr Kevin Chua Medical & AestheticsSo named for the technology where laser pulses are delivered in picosecondsa unit of measurement that refers to one trillionth of a seconda PicoWay facial sends small bursts of intense laser energy deep into the skin to stimulate its natural healing abilities. The short pulsations mean that less heat is emitted during the procedure, so you neednt worry about post-treatment burns. Benefits of the treatment, which is suitable for most skin types, include plumper, suppler skin with improved tone and texture.

Related article:Spa Awards 2020 Best Rejuvenating Facial: PicoWay RESOLVE

BEST RESURFACING FACIALPico Fractional Laser Treatment$300 for 60 minutes, Calvin Chan Aesthetic & Laser ClinicVia short but intense pulses of laser energy delivered deep into the dermis, the skin is transformed from the inside out as new collagen and elastin is produced to significantly improve the appearance of pitted acne scars, pigmentation and wrinkles. And if youre worried about downtime, dont. The surface of the skin is left intact while the deep tissue heals, which means theres no recovery time involved.

BEST SHAPING & TIGHTENING FACIALBiologique Recherche Remodeling Face $380 for 90 minutes, Freia AestheticsThis kicks off with a 60-minute booster customised to your skins needs, followed by a proprietary massage that promotes blood flow and stimulates the lymph nodes for a detoxifying effect. The Remodelling Face machine then uses a bespoke blend of electric, galvanic and high-frequency currents to enhance the benefits of the preceding steps, and deliver product actives deeper and more efficiently into skin for a supreme lifting, tightening and plumping effect.

BEST SOOTHING FACIALSeriously Soothing $209 for 90 minutes, EPIONLiving up to its name, this hydrates and calms thirsty skin with a side of sensitivity. Ultrasonic energy is first used to give skin a deep cleanse. This is followed by a dose of much-needed hyaluronic acid and the application of a soothing face mask. The final step: LED red light therapy to help stimulate collagen production and reduce redness or inflammation.

Related article:Cindy Crawford Shows How She Stays Fabulous At Every Age In Our February Issue

Read this article:
Spa Awards 2020: Best Specialised Solutions Tackle Every Skin Concern - Harper's Bazaar Singapore

Recommendation and review posted by Bethany Smith

Liposuction is a surgical procedure to remove extra fat from your body. It started in the 1980s and has become one of the most popular plastic surgeries in the US. An estimated 258,000 Americans got it in 2018.

Today, you can expect to pay around $3,500 for liposuction and most health insurance plans won't cover the cost. But if you're willing to pay the price, liposuction is a relatively safe and quick procedure that can help you shed fat that diet and exercise can't.

Here's what you need to know about how liposuction works and why it's not a weight-loss tool.

Liposuction is a 1-to2-hour-long procedure where fat cells are permanently removed from your body, usually for cosmetic reasons. People who get liposuction don't do it to lose large amounts of weight but rather to help sculpt the shape of their body.

Some of the most common places to have fat removed are the belly, thighs, buttocks, arms, back, the upper neck just under the chin, and jawline/jowls.

Depending on where you're getting the procedure, doctors will either provide a local anesthetic to numb the area of operation or they will give you a general anesthetic so you're unconscious during the procedure.

Then, surgeons will often inject into the area of operation a solution containing a mix of saline solution, a numbing medicine, and medicine the decreases bleeding. This is to help the skin and fat separate from important structures like muscles and blood vessels so they aren't damaged during the suctioning process.

After that, the surgeon inserts a long metal instrument called a cannula under your skin. The cannula then vacuums out your fat. During this process, surgeons may also use a smaller microcannula to remove fat in nearby areas to achieve a more natural, smoother contour.

Once the fat is removed through liposuction it can be discarded or it can be injected back into your body to enhance features like breasts, buttocks, or face. Or, more recently, in the last decade or so, liposuction has also been used to retrieve stem cells a type of cell that can form other specialized cells in the body for laboratory research.

After liposuction, your surgeon will likely recommend you wear a temporary band or brace over the area of operation to help the skin heal. The band or brace also helps prevent fluid from building up in the area of operation where the fat was removed, between the skin and deeper structures like muscles and blood vessels.

Whether you are awake or asleep during liposuction, you shouldn't feel any pain during the procedure, says Marco A. Pelosi II, MD, a cosmetic surgeon with experience performing liposuction procedures. The recovery, also, should be a relatively mild process.

After getting liposuction, you will feel soreness similar to a muscle ache. "The level of this soreness is typically a 2 or 3 out of 10 for a few weeks," says Pelosi, adding that you should be able to go back to work in 2 to 3 days.

Ongoing pain near the area where the cannula was inserted is a risk of liposuction, and if the pain grows or pain killers don't help, you should tell your surgeon.

According to the Cleveland Clinic, you should not use liposuction as a weight loss alternative. It recommends that if you want to lose weight, you should first try diet and exercise, then use liposuction to take care of more stubborn areas like the chin or belly fat.

Moreover, research shows that people who keep up other weight loss practices like a healthy diet and exercise will see better results after liposuction and keep fat from returning to a particular area.

This is because while liposuction permanently removes fat cells from your body, there is nothing to stop the remaining fat cells from getting bigger if you gain more weight.

There are some important safety tips to look for when choosing a liposuction provider.

First, look for a facility that meets national safety requirements. You can verify if a facility is accredited on the American Society of Plastic Surgeons' website here.

Pelosi says that doctors should also do blood work testing and medical clearances before a liposuction procedure to ensure your safety. These tests are to make sure you can safely undergo general anesthesia without complication. If, for example, you have an infection or are pregnant, you may not qualify for the surgery.

Last, but not least, is to look for a surgeon who is board-certified in performing these types of procedures and also has extensive experience with liposuction procedures so you know that they are well versed in the technique. To find out more about a practitioner's experience with liposuction, you can check the American Society of Plastic Surgeons' website.

See more here:
What is liposuction? How the procedure works and how painful it is - Insider - INSIDER

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continue reading here:
Stem Cell Therapy Market Statistics, Trends, Size, Growth Opportunities, Share Demand and Forecast to 2025 - Jewish Life News

Recommendation and review posted by Bethany Smith

The market analysis and insights included in the Cosmetic Skin Care market report presents key statistics on the market status of global and regional manufacturers and is an essential source of guidance which provides right direction to the companies and individuals interested in the industry. To prosper in this competitive market place, businesses are highly benefited if they adopt innovative solutions such as this Cosmetic Skin Care market research report. This wide-ranging market research report acts as a backbone for the success of business in any sector. The market drivers and restraints have been explained in the report with the use of SWOT analysis.

Global cosmetic skin care marketis set to witness a substantial CAGR of 5.5% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Increasing self-consciousness among population and rising demand for anti- aging skin care products are the factor for the market growth.

Global Cosmetic Skin Care Market By Product (Anti-Aging Cosmetic Products, Skin Whitening Cosmetic Products, Sensitive Skin Care Products, Anti-Acne Products, Dry Skin Care Products, Warts Removal Products, Infant Skin Care Products, Anti-Scars Solution Products, Mole Removal Products, Multi Utility Products), Application (Flakiness Reduction, Stem Cells Protection against UV, Rehydrate the skins surface, Minimize wrinkles, Increase the viscosity of Aqueous, Others), Gender (Men, Women), Distribution Channel (Online, Departmental Stores and Convenience Stores, Pharmacies, Supermarket, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026 ;

Complete report on Global Cosmetic Skin Care Market Research Report 2019-2026 spread across 350 Pages, profiling Top companies and supports with tables and figures

Market Definition: Global Cosmetic Skin Care Market

Cosmetic skin care is a variety of products which are used to improve the skins appearance and alleviate skin conditions. It consists different products such as anti- aging cosmetic products, sensitive skin care products, anti- scar solution products, warts removal products, infant skin care products and other. They contain various ingredients which are beneficial for the skin such as phytochemicals, vitamins, essential oils, and other. Their main function is to make the skin healthy and repair the skin damages.

Key Questions Answered in Global Cosmetic Skin Care Market Report:-

Our Report offers:-

Top Key Players:

Market Drivers:

Market Restraints:

Key Developments in the Market:

Customize report of Global Cosmetic Skin Care Market as per customers requirement also available.

Market Segmentations:

Global Cosmetic Skin Care Market is segmented on the basis of

Market Segmentations in Details:

By Product

By Application

By Gender

By Distribution Channel

By Geography

North America

Europe

Asia-Pacific

South America

Middle East & Africa

Competitive Analysis: Global Cosmetic Skin Care Market

Global cosmetic skin care market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cosmetic skin care market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:corporatesales@databridgemarketresearch.com

Continued here:
COSMETIC SKIN CARE MARKET ENHANCEMENT AND ITS GROWTH PROSPECTS FORECAST 2019 TO 2026 - Reporting 99

Recommendation and review posted by Bethany Smith

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors expressed PD-L1 (Combined Positive Score [CPS] 10). Based on an interim analysis conducted by an independent Data Monitoring Committee (DMC), first-line treatment with KEYTRUDA in combination with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine/carboplatin) demonstrated a statistically significant and clinically meaningful improvement in PFS compared to chemotherapy alone in these patients. Based on the recommendation of the DMC, the trial will continue without changes to evaluate the other dual primary endpoint of overall survival (OS). The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.

Triple-negative breast cancer is an aggressive malignancy. It is very encouraging that KEYTRUDA in combination with chemotherapy has now demonstrated positive results as both a first-line treatment in the metastatic setting with this trial, and as neoadjuvant therapy in the KEYNOTE-522 trial, said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. We look forward to sharing these findings with the medical community at an upcoming congress and discussing them with the FDA and other regulatory authorities.

The KEYTRUDA breast cancer clinical development program encompasses several internal and external collaborative studies. In addition to KEYNOTE-355, in TNBC these include the ongoing registration-enabling studies KEYNOTE-242 and KEYNOTE-522.

About KEYNOTE-355

KEYNOTE-355 is a randomized, two-part, Phase 3 trial (ClinicalTrials.gov, NCT02819518) evaluating KEYTRUDA in combination with one of three different chemotherapies (investigators choice of either nab-paclitaxel, paclitaxel or gemcitabine/carboplatin) compared with placebo plus one of the three chemotherapy regimens for the treatment of locally recurrent inoperable or mTNBC that has not been previously treated with chemotherapy in the metastatic setting. Part 1 of the study was open-label and evaluated the safety and tolerability of KEYTRUDA in combination with either nab-paclitaxel, paclitaxel or gemcitabine/carboplatin in 30 patients. Part 2 of KEYNOTE-355 was double-blinded, with dual primary endpoints of OS and PFS in all participants and in participants whose tumors expressed PD-L1 (CPS 1 and CPS 10). The secondary endpoints include objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and safety.

Part 2 of KEYNOTE-355 enrolled 847 patients who were randomized to receive KEYTRUDA (200 mg intravenously [IV] on day 1 of each 21-day cycle) plus nab-paclitaxel (100 mg/m2 IV on days 1, 8 and 15 of each 28-day cycle), paclitaxel (90 mg/m2 IV on days 1, 8 and 15 of each 28-day cycle) or gemcitabine/carboplatin (1,000 mg/m2 [gemcitabine] and Area Under the Curve [AUC] 2 [carboplatin] on days 1 and 8 of each 21-day cycle); or placebo (normal saline on day 1 of each 21-day cycle) plus nab-paclitaxel (100 mg/m2 IV on days 1, 8 and 15 of each 28-day cycle), paclitaxel (90 mg/m2 IV on days 1, 8 and 15 of each 28-day cycle) or gemcitabine/carboplatin (1,000 mg/m2 [gemcitabine] and AUC 2 [carboplatin] on days 1 and 8 of each 21-day cycle).

About Triple-Negative Breast Cancer (TNBC)

TNBC is an aggressive type of breast cancer that characteristically has a high recurrence rate within the first five years after diagnosis. While some breast cancers may test positive for estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2 (HER2), TNBC tests negative for all three. As a result, TNBC does not respond to therapies targeting these markers, making it more difficult to treat. Approximately 15-20% of patients with breast cancer are diagnosed with TNBC.

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,000 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [combined positive score (CPS) 10], as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High (MSI-H) Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Selected Important Safety Information for KEYTRUDA

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC patients receiving KEYTRUDA as a single agent, including Grades 3-4 in 3.2% of patients, and occurred more frequently in patients with a history of prior thoracic radiation (17%) compared to those without (7.7%). Pneumonitis occurred in 6% (18/300) of HNSCC patients receiving KEYTRUDA as a single agent, including Grades 3-5 in 1.6% of patients, and occurred in 5.4% (15/276) of patients receiving KEYTRUDA in combination with platinum and FU as first-line therapy for advanced disease, including Grades 3-5 in 1.5% of patients.

Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (<0.1%). Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.

Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib)

Immune-Mediated Hepatitis

KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.4%), and 4 (<0.1%). Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.

Hepatotoxicity in Combination With Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of Grades 3 and 4 ALT and AST elevations compared to KEYTRUDA alone. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased ALT (20%) and increased AST (13%) were seen. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed.

Immune-Mediated Endocrinopathies

KEYTRUDA can cause adrenal insufficiency (primary and secondary), hypophysitis, thyroid disorders, and type 1 diabetes mellitus. Adrenal insufficiency occurred in 0.8% (22/2799) of patients, including Grade 2 (0.3%), 3 (0.3%), and 4 (<0.1%). Hypophysitis occurred in 0.6% (17/2799) of patients, including Grade 2 (0.2%), 3 (0.3%), and 4 (<0.1%). Hypothyroidism occurred in 8.5% (237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC (16%) receiving KEYTRUDA, as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. Hyperthyroidism occurred in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade 2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 0.2% (6/2799) of patients.

Monitor patients for signs and symptoms of adrenal insufficiency, hypophysitis (including hypopituitarism), thyroid function (prior to and periodically during treatment), and hyperglycemia. For adrenal insufficiency or hypophysitis, administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA for Grade 2 adrenal insufficiency or hypophysitis and withhold or discontinue KEYTRUDA for Grade 3 or Grade 4 adrenal insufficiency or hypophysitis. Administer hormone replacement for hypothyroidism and manage hyperthyroidism with thionamides and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and withhold KEYTRUDA and administer antihyperglycemics in patients with severe hyperglycemia.

Immune-Mediated Nephritis and Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue for Grade 3 or 4 nephritis.

Immune-Mediated Skin Reactions

Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur. Monitor patients for suspected severe skin reactions and based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA and administer corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for specialized care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.

Other Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue in patients receiving KEYTRUDA and may also occur after discontinuation of treatment. For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less following corticosteroid taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.

The following clinically significant immune-mediated adverse reactions occurred in less than 1% (unless otherwise indicated) of 2799 patients: arthritis (1.5%), uveitis, myositis, Guillain-Barr syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and encephalitis. In addition, myelitis and myocarditis were reported in other clinical trials, including classical Hodgkin lymphoma, and postmarketing use.

Treatment with KEYTRUDA may increase the risk of rejection in solid organ transplant recipients. Consider the benefit of treatment vs the risk of possible organ rejection in these patients.

Infusion-Related Reactions

KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% (6/2799) of patients. Monitor patients for signs and symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Immune-mediated complications, including fatal events, occurred in patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of 23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2 (9%) developed severe hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute GVHD after allogeneic HSCT have also been reported in patients with lymphoma who received a PD-1 receptorblocking antibody before transplantation. Follow patients closely for early evidence of transplant-related complications such as hyperacute graft-versus-host disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease (VOD), and other immune-mediated adverse reactions.

In patients with a history of allogeneic HSCT, acute GVHD (including fatal GVHD) has been reported after treatment with KEYTRUDA. Patients who experienced GVHD after their transplant procedure may be at increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA vs the risk of GVHD in these patients.

Increased Mortality in Patients With Multiple Myeloma

In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with a PD-1 or PD-L1 blocking antibody in this combination is not recommended outside of controlled trials.

Embryofetal Toxicity

Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.

Adverse Reactions

In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).

In KEYNOTE-002, KEYTRUDA was permanently discontinued due to adverse reactions in 12% of 357 patients with advanced melanoma; the most common (1%) were general physical health deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized edema (1%). The most common adverse reactions were fatigue (43%), pruritus (28%), rash (24%), constipation (22%), nausea (22%), diarrhea (20%), and decreased appetite (20%).

In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (20%) with KEYTRUDA was diarrhea (28%).

In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most common adverse reactions (20%) with KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%), decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia (20%).

In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101 patients. The most frequent serious adverse reactions reported in at least 2% of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.

In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients with advanced NSCLC; the most common were pneumonitis (3%), death due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%). The most common adverse reaction (20%) was fatigue (25%).

In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis (1.8%). The most common adverse reactions (20%) were decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).

Adverse reactions occurring in patients with SCLC were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.

In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in 12% of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most common adverse reactions (20%) were fatigue (33%), constipation (20%), and rash (20%).

In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 16% of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common adverse reactions (20%) were nausea (51%), fatigue (49%), constipation (37%), vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased appetite (29%), stomatitis (26%), and cough (22%).

In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of 192 patients with HNSCC. Serious adverse reactions occurred in 45% of patients. The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (20%) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.

In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients with cHL. Serious adverse reactions occurred in 16% of patients; those 1% included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (20%) were fatigue (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea (20%), and rash (20%).

In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of patients and included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died within 30 days of start of treatment. The most common adverse reactions (20%) were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia (28% each), cough (26%), fatigue (23%), and dyspnea (21%).

In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of 370 patients with locally advanced or metastatic urothelial carcinoma. Serious adverse reactions occurred in 42% of patients; those 2% were urinary tract infection, hematuria, acute kidney injury, pneumonia, and urosepsis. The most common adverse reactions (20%) were fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%), constipation (21%), rash (21%), and diarrhea (20%).

In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8% of 266 patients with locally advanced or metastatic urothelial carcinoma. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated patients; those 2% were urinary tract infection, pneumonia, anemia, and pneumonitis. The most common adverse reactions (20%) in patients who received KEYTRUDA were fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased appetite (21%), nausea (21%), and rash (20%).

In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in 11% of 148 patients with high-risk NMIBC. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.4%). Serious adverse reactions occurred in 28% of patients; those 2% were pneumonia (3%), cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis (2%), and urinary tract infection (2%). The most common adverse reactions (20%) were fatigue (29%), diarrhea (24%), and rash (24%).

Adverse reactions occurring in patients with gastric cancer were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.

Adverse reactions occurring in patients with esophageal cancer were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.

In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98 patients with recurrent or metastatic cervical cancer. Serious adverse reactions occurred in 39% of patients receiving KEYTRUDA; the most frequent included anemia (7%), fistula, hemorrhage, and infections [except urinary tract infections] (4.1% each). The most common adverse reactions (20%) were fatigue (43%), musculoskeletal pain (27%), diarrhea (23%), pain and abdominal pain (22% each), and decreased appetite (21%).

Read more from the original source:
Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for...

Recommendation and review posted by Bethany Smith

Created for Greatist by the experts at Healthline. Read more

Maybe the winter blues have you feeling down, or youre wondering if your crappy month could actually be depression. So you pull out your phone, Google mood boosters, and cross your fingers that youll get better suggestions than bubble baths and homemade face masks.

The truth is, your happiness is influenced by a whole mess of factors. Brain chemicals and hormones make a big difference. Take serotonin, for instance. This tiny chemical is a whole mood.

Serotonin is a neurotransmitter found in your brain, blood, and digestive system. It ships messages feel-good, stabilizing ones between nerve cells. Thats why its been dubbed the happy hormone or happy chemical.

Serotonin helps you sleep, controls cravings, and keeps your digestion regular (which is a low-key mood booster on its own, amiright?). Studies are still unclear on whether serotonin is directly responsible for good vibes or if it simply plays a critical role in regulating your nervous system.

Since serotonin is basically your wellness ride-or-die, bad things happen when it gets too low. Some of this is theoretical its not like we can stick a needle in your brain to check the serotonin level, and there are no blood tests yet. But the theory has yet to be proven wrong.

Symptoms of a serotonin slump include:

Weve all heard the jokes about tryptophan, the mystical amino acid in turkey that puts you into a food coma. Research has also linked tryptophan-heavy diets with feeling happier and calmer.

Sure, tryptophan makes you sleepy, but your body also uses it to create serotonin. Some of the strongest evidence for the serotonin theory comes from studies that show low intake of tryptophan is linked to depression.

+ = =

More tryptophan equals more serotonin and more good vibes all around.

Upping your serotonin isnt as simple as smashing turkey legs on repeat. Your brain has an uber-protective covering called the blood-brain barrier, and good ol tryptophan has to wait in line to be admitted just like everyone else.

Good news: Research suggests that pairing tryptophan with carbs bypasses this issue.

Pro tip:

Since carbs tell your body to release insulin, and insulin speeds up amino acid absorption, eat your tryptophan-rich meals with 2530 grams of carbs.

Some people need supplements or even antidepressants to get their serotonin flowing. But there are a few natural ways to boost this brain chemical.

Your mission is to load up on tryptophan, which your body can convert into happy, healthy serotonin. But eating one trypto-laced turkey leg wont make much difference in your serotonin levels.

Instead, a steady diet of tryptophan-rich foods paired with carbs could raise your serotonin levels over time.

Here are some of the best tryptophan-heavy foods to fill up on.

Eggs specifically the yolks are packed with tryptophan. Theyre full of amino acids and antioxidants like tryptophan, tyrosine, choline, biotin (great for hair, skin, and nails!), and omega-3 fatty acids.

Pro tip: For all the benefits without extra cholesterol, go for hard-boiled instead of fried. Remember to pair it with a carb for maximum effect. Toast or oatmeal, anyone?

Pineapple is a triple threat when youre feeling drained or sick. It has tryptophan, a bit of serotonin, and lots of bromelain an enzyme proven to reduce inflammation.

Pro tip: Pack two tryptophan powerhouses into one meal with a Hawaiian-style chicken and pineapple dish served over rice (dont forget the carb!).

Heres one more reason to order the cheese board next time youre out for happy hour.

In a study of 25 healthy people, participants reported significantly better moods during a 4-day diet high in tryptophan than during their subsequent 4-day diet low in tryptophan. And which food made them so happy? Mozzarella, for starters.

Bananas are already famous for their potassium content. But wait theres more! The National Sleep Foundation recommends eating half a banana 1 hour before bedtime because of the fruits tryptophan content. Since fruit is already full of good carbs, its a perfect pairing.

You know where this is going. Yep, salmon is full of tryptophan too. Aside from fueling your serotonin reserves, salmon floods your body with omega-3 fatty acids, which have been found to reduce the risk of fatal heart disease.

Tofu is the best serotonin-boosting food for vegans and vegetarians. Its also one of the proteins Cleveland Clinic recommends dishing out to cure the winter blues.

Pro tip: Look for calcium-set tofu for a meal that will help you feel happier and stronger.

Remember the first time you heard the word tryptophan? It was probably on a long-ago Thanksgiving. We all know turkey has tryptophan. And now you know tryptophan is good for more than summoning Mr. Sandman it also unlocks your serotonin potential.

Good news for snackers: Every nut and seed you can think of contains tryptophan. Bonus points for nuts because studies show that a handful a day may help keep the oncologist and cardiologist away!

Pro tip: Round out your good vibes snack with dried fruit (good carbs!) instead of chocolate for healthier noshing.

Eating your feelings isnt always the best path to happiness. Keep your serotonin flowing with these lifestyle tweaks too:

H2O keeps your brain and the rest of your body running smoothly. Next time youre feeling low, try downing a big glass of water. Rinse and repeat.

Aerobic exercise releases tryptophan and endorphins into your bloodstream.

Research suggests serotonin levels dip in winter. Sunshine seems to jump-start your bodys serotonin production.

Theres more research to be done, but this serotonin-and-sunshine connection could explain seasonal affective disorder (SAD). On a related note, get your level of Vitamin D checked and take a supplement if indicated.

A happy, healthy diet goes beyond tryptophan-rich foods. Recent studies indicate that eating a balanced diet could help protect against depression.

Processed foods full of artificial sweeteners and food coloring can screw with your gut bacteria, which affects your mood and overall wellness.

Some research suggests that massage lowers cortisol, which is the ying to serotonins yang. In a 2012 study of pregnant women with depression, two 20-minute massages a week decreased anxiety and increased serotonin after about 4 months.

Sometimes eating all the turkey and getting all the sunshine still doesnt lift your spirits. If youre here for serotonin boosters because day-to-day life feels like a struggle, you might be depressed.

Talk to your doctor about antidepressants, supplements, and therapy options.

Some people have naturally lower levels of serotonin. This brain chemistry imbalance might feel like a permanent cloud over your head, a lack of motivation, or even intense irritability.

Doctors sometimes prescribe selective serotonin reuptake inhibitors (SSRIs) for people who have chronically low serotonin. SSRIs prevent your happy chemical from being reabsorbed too quickly, so serotonin sticks around longer, prolonging good vibes.

Here are some common SSRIs used to treat depression:

In the last few years, SSRIs have gotten some criticism. One article in 2015 even called them the marketing of a myth. Why? Because even though SSRIs have been in pharmacists rotation since the 1980s, research still hasnt totally backed up their effectiveness.

The pills do boost serotonin in the bloodstream, but the jurys still out on whether they do the same in the brain. A 2014 study of mice suggested serotonin might not factor into depression at all. In 2015, another study linked serotonin with vulnerability to stress.

Serotonin also has an anti-inflammatory effect, and research has shown that people with depression have higher indicators of inflammation in blood tests.

So whats the verdict? SSRIs seem to help people with depression, but the reasons are more complicated than a simple low serotonin = bad mood equation.

You could fill up on tryptophan with turkey, cheese, and nuts or you could pop a few tryptophan pills. Just remember to check with your doctor before downing any new supplement.

Its important to know if supplements will interact with your prescription meds, over-the-counter meds, vitamins, or even herbal remedies.

Be sure to research where your supplement was manufactured and buy it from a reputable source the FDA doesnt monitor the quality and safety of supplements.

Pro tip:

Never buy a supplement from a brand you cant easily research and verify. Its important to know whether the product youre buying is pure and high-quality.

These are the most tried-and-true supplements for bumping your mood into a happy place:

Tryptophan supplements are waaay more potent than turkey, salmon, or tofu. That means these high doses of tryptophan are more likely than food to cross the blood-brain barrier. You can buy tryptophan supplements online.

This funny-sounding supplement is actually a flowering plant. Its been touted as a mood booster for years, but research is mixed.

Proceed with caution:

St. Johns wort doesnt play nice with some prescription meds including birth control and cancer drugs. Also avoid taking it with antidepressants or other serotonin-boosting meds.

You can buy St. Johns wort supplements online.

Eating more probiotics could boost your tryptophan levels (and you know what that means: more serotonin!).

The beauty of probiotics is that theyre available in so many forms. Lets count the ways: kombucha, tempeh, yogurt, kimchi, sauerkraut, and oh yes, probiotic supplements.

In 2013, a small study suggested that 5-HTP could be just as effective as antidepressants for mild depression. Further research hasnt been as promising, but its still possible this supplement has the power to enter your brain and kick-start serotonin production.

You can buy 5-HTP supplements here.

PSA:

You can have too much of a good thing! Serotonin overdose is real. Dont mix supplements with SSRIs. Chat with your doctor before switching supplements or changing your SSRI dosage.

If you feel sad or sluggish all the time, it might be time to call a doctor or make an appointment with a therapist. Mood disorders are complex. It takes more than a supplement, a massage, or half a banana at night to treat depression.

After an appointment with a healthcare provider, you might start taking an SSRI or another antidepressant. Or you might be prescribed a different kind of therapy or treatment. Only a medical pro can give you a personalized plan for managing depression.

Serotonin is a neurotransmitter found in several parts of your body. Its best known for making you feel happy and healthy. There are natural ways to boost serotonin, but that doesnt mean you have to do it alone.

If you think you might have depression or another mood disorder, dont hesitate to call your healthcare provider and ask for help.

Visit link:
Serotonin FTW: How to Boost Your Happy Hormone - Greatist

Recommendation and review posted by Bethany Smith

FARMINGTON As a medical student at the University of Arizona, training to go into family medicine, Karren Seely watched as the curriculum circumnavigated or fully avoided topics relating to the health of lesbian, gay, bisexual, transgender and queer people.

There were no more than three classes over three years that covered LGBTQ issues and most focused on HIV/AIDS, she said. When she moved to Maine for the Maine Dartmouth Family Residency Program in 2011, it got worse.

The residency was actually more lacking than medical school, oddly enough, even though there were LGBTQ staff, Seely, 43, said. That was one of the disappointments. Any training that got done, I had to instigate. It just wasnt a priority and thats understandable because theyre trying to teach so much and the regulatory bodies that manage the education of students werent requiring residencies to teach that.

The knowledge she acquired was through conferences she sought out and her own lived experiences as a transgender woman.

Barriers like this, far from unique to the Maine Dartmouth program, illustrate one side of a problem many Mainers know well: Quality healthcare for members of the LGBTQ community is hard to come by. Not enough providers are informed enough to administer proper care, and even where there is good service, accessing it can be tough. Patients often face long waitlists or must travel far distances. Some avoid medical appointments altogether out of fear of mistreatment because of their orientation or identity.

About 67,000 LGBTQ people are living in Maine currently, roughly 6,000 to 12,000 of whom are transgender, according to Quinn Gormley, executive director of Maine Transgender Network.

Seely is one of just 22 medical practitioners in Maine and one of two in central Maine who are part of the only national network of providers dedicated to caring for the LGBTQ community, the GLMA: Health Professionals Advancing LGBTQ Equality Provider Directory. She works at Farmington Family Practice, under the Franklin Community Health Program of MaineHealth. The second is Maia Pinsky, of Gardiner Family Medicine, who was on maternity leave at press time but will be back in mid-February.

The directory can reveal some surprising statistics. Massachusetts, for instance, has five times the population of Maine, but 13 times the number of LGBTQ-friendly providers. In context, Maine is more rural and Boston is home to one of the countrys leading LGBTQ health care, education, research and advocacy groups, Fenway Health. Still, Maines most rural neighbor, Vermont, has less than half the population, but three quarters the number of providers on the directory. There is definitely a shortage of providers in Maine, Gormley said.

The LGBTQ community is one of the major underserved populations, Seely said. For example, lesbian women are more likely to have breast cancer, and were not sure why.

The suicide rate among lesbian, gay and bisexual youth is significantly higher; its nine times higher than the national average for transgender people. Nearly 50% of transgender adults have attempted suicide at least once in their life. Theres a higher rate of smoking and substance use, and this is all largely attributed to societal stigma and the chronic trauma that is associated with that.

While some LGBTQ health needs are specific to the community, like hormone therapy or sex reassignment surgery, health professionals familiar with the population, research institutes and advocates say that most care belongs in primary care or family medicine settings. Much of the required care is universal treating sore throats, allergies, infections, pains and sprains or other conditions like heart disease, diabetes and cancer. Other needs simply require awareness: knowing that just because a lesbian woman is not having penetrative sex with men, she still needs gynecological exams; that because estrogen is a risk factor for breast cancer, transgender women over 50 who have been taking estrogen for more than five years should receive mammograms; and so on, according to Gormley.

Treating (the LGBTQ community) is not particularly complicated, Seely said. You just need to be familiar with the standards of care and get to know the patients.

Gormley echoed that sentiment.

The view that LGBTQ care is a specialty is unfortunate, because something we hear a lot from doctors we train is that they dont think they have a lot of LGBTQ patients, which means they dont have the right data, said Gormley, who runs dozens of trainings a year in Maine and has educated thousands of medical providers. A lack of education and normalcy in LGBTQ health issues results in a lack of competent care.

A lot of doctors are nervous about being labeled as the queer or trans doctor because very quickly they end up having a practice thats only queer and trans and I dont know why. I think were great patients.

Gormley vividly recalls one of the low moments in her own healthcare history. Seven years ago, she went to an emergency room in Lincoln County after breaking her arm while working at a wood shop.

I sit down at the check-in desk with teary eyes because my arm was broken, and across from me is this girl who was in my homeroom in high school and who I had gone to school since kindergarten with, Gormley said.

She knew exactly who I was. I had just come out, and my ID and insurance card didnt match, and she told me that the emergency room wouldnt provide care for me because my identifications didnt match, and she told me to try another hospital. This was a person who knew who I was and knew why my information wouldnt match. It was a hospital where I had received all my care for 20 years.

Bureaucratic things like that happen a lot, and its incredibly embarrassing and often the excuse for providers and even more often front-end workers who dont want to deal with you because of your orientation or identity or they dont want to solve the problem of someone who doesnt fit through the system easily.

RURAL HEALTHCARE

Nowhere in Maine do the issues of accessible and quality LGBTQ healthcare intersect stronger than they do in its rural areas.

Census data shows that nationwide, people in rural communities are more likely to have low incomes and less likely to have health insurance. LGBTQ populations are also more likely to have low incomesand less likely to have health insurance.

LGBTQ healthcare is an area of inequity everywhere in the United States, Gormley said. I think what makes Maine unique is that the intersection of rural healthcare and poverty is particularly strong for us.

As of 2016, Maine was the most rural state in the country, with 61.6% of its population considered rural.

LGBTQ people living in rural areas are at a statistical disadvantage, Gormley said. Maines rural health system is lacking already these are the people already struggling to meet the basic needs of the communities they serve. Anyone else who isnt going to fit cleanly into expectations of what those needs are is going to struggle.

It is in this realm where providers like Seely are setting an example for the state. While she moved to Maine in part to escape the Arizona heat and in part because she was drawn to the Maine Dartmouth program, she said she decided to continue practicing in Farmington for a reason.

And thats because physicians are needed the most in the rural areas, and I knew that LGBTQ-friendly physicians would be needed even more than just any other physician in rural areas, she said.

Right now, she is the primary care provider for 1,700 patients, about 5% roughly 85 of whom are LGBTQ, she said. Some come to Farmington from smaller towns such as Rumford and others from bigger cities including Bangor, Lewiston-Auburn and Augusta.

Currently at capacity, the only new patients Seely will take on are LGBTQ.

I dont believe weve reached that point, Seely said about having to turn LGBTQ patients away. Were trying hard not to reach that point thats partly why Im only accepting LGBTQ patients at the moment.

Generally it isnt like a floodgate kind of situation. Its more here and there. People come in and then I accept them and get them the help they need. Sometimes I work as a consultant for local providers who just havent felt comfortable or experienced enough to help their LGBTQ patients.

SEELYS APPROACH

Hanging up in the four rooms where Seely sees patients at Farmington Family Practice are lists of resources from OUT Maine, an organization that empowers and educates rural LGBTQ youth in Maine; brightly colored flyers titled Gender 101 and rainbow-colored stickers indicating that the rooms are safe spaces for LGBTQ folks. Visible signs of support, she said, can help put patients at ease.

I know some of my patients have had bad experiences (with doctors) in the past, and theyve expressed that to me but I dont really ask for details, Seely said. Mostly I just apologize and tell them that this is a safe space.

I know sometimes its outright hostility from doctors and sometimes its just the ignorance side of things. On rare occasions, patients end up getting triggered and they hear what theyve heard in the past, and it may not necessarily be what the provider was trying to do.

Some of the best ways for doctors to avoid harming LGBTQ patients, Seely said, are to not misidentify their names, gender identities or sexualities and to use their preferred pronouns, such as she/her/hers, he/him/his, or the gender-neutral they/them/their.

The best way to do that is to ask the patients, Seely said. When in doubt, the biggest thing is: dont make assumptions. In our charts, we have the patients name that they go by, whether its legal or not, listed there, and what their preferred pronouns are.

When she sees her patients, Seely makes sure to ask if the names and pronouns on file are still accurate. She hopes that in the future, intake forms at Farmington Family Practice and elsewhere will ask patients to self-identify sexual orientation and gender identity to make the sharing of that information easier for people. It can be difficult to bring up without being prompted.

Understanding that coming out isnt a one-time experience is something that is important for doctors to keep in mind, Seely said.

Its a lifelong process, because for the most part, people dont know youre LGBTQ unless you tell them, so every time you encounter somebody youre thinking about who is safe to talk to about that versus not and that kind of thing. Its important to understand that thats a constant process, and even when theyre coming to see their doctor or their doctors staff, any negative experience can be significantly magnified.

She cautioned that doctors must especially value confidentiality with LGBTQ patients.

Outing patients, particularly minor patients, importantly, is right up there with the complications of, say, dealing with pregnant teenagers, Seely said. It can be outright dangerous. Teenagers can get thrown out of their home.

According to the Center for American Progress, while LGBTQ youth comprise between 5% and 10% of the youth population, about 40% of the homeless youth population is LGBTQ.

This reality is hard for Seely to forget: She was kicked out of her own home at age 20 when she came out as a transgender woman to her birth parents.

ROLE OF DIRECTORIES

Provider directories, like the one from GLMA: Health Professionals Advancing LGBTQ Equality, are a boon to accessible care for the LGBTQ community. They are an anonymous way to find reliable for the most part medical care. They are also a modern version of the whisper networks that allowed the LGBTQ, and especially trans, community to find good doctors during a time when, as Gormley said, it was considered best practice for providers who served us to actively prevent us from talking to each other.

With the policing of gender identities, doctors figured out pretty quickly that when we talk to each other, we tell each other the answers to things that get you through, she said.

There are no formal training requirements (or fees) for doctors to register for and appear in the GLMA: Health Professionals Advancing LGBTQ Equality directory, and because of that, the organization has struggled to vet every provider on its list. One Albion-based provider, for example, is still on the directory, despite having left the practice at least a year ago, according to an official at the Lovejoy Health Center. But seeking inclusion on the resource, despite its flaws, can indicate that a provider is at least interested in reaching out to the LGBTQ community.

Being a part of a list really shows its a huge first step for a lot of people, said Scott Nass, president of GLMA: Health Professionals Advancing LGBTQ Equality and a family physician in Palm Springs, California.

I know a lot of people welcome LGBTQ folks in their practice but hesitate to put (their) name on the list. But letting the LGBTQ community know youre there available, offering whatever support or expertise you can, is really important.

The organization asks providers to take steps to make their practice more inclusive and continue to educate themselves in the latest standards of care for the LGBTQ community, Nass said. An impending update to the database will include more avenues for patients to submit feedback about their experiences with particular doctors.

MaineTransNet has been building a Maine-specific provider directory for the LGBTQ community, called the Maine Queer Health Community Database. Currently in its beta form, there are already 30 provider listings and Gormley said she expects about 50 by the end of February.

Our thought in investing in a database was: aggregate and put the information in a central space so everyone can access it, Gormley said. We want it to be able to be more specific (than GLMA: Health Professionals Advancing LGBTQ Equality) and something thats really designed for Maine. Its not helpful for someone in Presque Isle that theres a really great doctor in Portland.

In the Maine Queer Health Community Database, there are options for community members to leave reviews, and there are also more specific search categories. For instance, people can look for providers based on region and whether or not someone accepts MaineCare.

You can also search using a broader definition of provider, Gormley said. In addition to medical and mental health providers, there are safe people on the database to go to to get your hair cut or for hair removal just a broader scope of wellness care.

Outside of the directories, many members of the LGBTQ community also share information about good or bad providers over Facebook groups and other social media.

HOPE

Despite challenges that persist, Maine has come a long way in recent years in terms of addressing health inequities in the LGBTQ community.

Penobscot Community Health Care has been recognized by the Human Rights Commission for the past eight years as an LGBTQ Healthcare Equality Leader. In 2015, the Barbara Bush Childrens Hospital at Maine Medical Center opened the states first-ever gender clinic though there is a waitlist for appointments. The Mabel Wadsworth Center in Bangor was awarded MaineTransNets first-ever accolade for outstanding transgender healthcare in 2019.

The Health Equity Alliance founded Maines first annual LGBTQ+ Healthcare Conference in 2015, held in Augusta, and in Lewiston, Bangor and Farmington in successive years.

The overall expansion of MaineCare and the addition of transgender medical care coverage have created a massive change in the conversation just in the last six months, Gormley said. MaineTransNet is currently working on defining the boundaries of that coverage, which Gormley said was left vague by the Department of Health and Human Services.

In the future, she hopes to see legislation that would increase MaineCare reimbursement rates so that more providers are willing to work with patients on MaineCare.

Another part of Gormleys vision for a better Maine circles back to what Seely noticed was lacking in her medical school and residency programs: universal education on the LGBTQ community at-large.

Other states have started requiring practitioners to include LGBTQ competency within their continuing education and within medical and social work education wed really like to see that become a requirement in Maine, Gormley said. Most practitioners are well-intentioned but nervous they dont want to hurt anybody and I think once theyve had the ability to have the things that make them anxious addressed, theyd become more enthusiastic about providing care to our community.

It boils down to this, Gormley said: If (doctors) were more familiar with our bodies, theyd know how to treat our bodies better; if they knew how to talk to us, wed be more comfortable talking to them. Health inequities in the LGBTQ community are a result of stigma and a lack of access, not because our bodies are different.

Previous

Next

View post:
Farmington doctor leads by example when it comes to LGBTQ care in rural Maine - Kennebec Journal & Morning Sentinel

Recommendation and review posted by Bethany Smith

Inhis last interview with a Los Angeles Timessports columnist, Kobe Bryant, of course, talked about basketball and the LA Lakers. But he also spoke about bein...

Inhis last interview with a Los Angeles Timessports columnist, Kobe Bryant, of course, talked about basketball and the LA Lakers.

But he also spoke about being a family man and how he wanted to elevate youth and womens sports, according to audio of the interview released by the LA Times Saturday.

When asked why he didnt attend many Lakers home games, Bryant said hed rather spend time at home.

I have gone through 20 years of the majority of my career with my kids Natalia and Gianna without being able to have that consistently, Bryant said.

So for me to make a trip up to the Staples Center, that means Im missing the opportunity to spend another night with my kids, and I know how fast it goes. Natalia is 16 and Gianna is 13. So that time came and went and so I want to make sure that the days Im away from them, are days that I absolutely have to, he said. Id rather just be hanging with them.

The interview is from October, just a few months before Bryant, his 13-year-old daughter Gianna and 7 others were killed in a helicopter crash. Columnist Arash Markazi decided to drive two hours to meet Bryant for a 17-minute interview.

It was one of the best decisions Ive ever made in my career, Markazi wrote.

He loved Giannas curiosity

Markazi asked Bryant abouthis relationship with Gianna, who went by Gigi, and coaching her youth basketball team.

Its a trip to see her move and the expressions that she makes, Bryant said. Its a trip, you know, the genetics. Genetics is a real thing, man.

He continued: What I love about Gigi is her curiosity about the game Even in a very heated situation in a game where its very competitive and back and forth, she can detach herself and come over and ask a very specific questions, which is not common.

All of our girls can do that, Bryant said, but the part that I think is most exciting is that its her curiosity and her ability to think critically in tight situations, (thats) pretty damn cool.

Bryant was asked about imagining his daughter moving away to play ball in college, and like many fathers he admitted, you never want to see your kids leave home, but eventually they have to.

He wanted to support girls and women in sports

Bryant also shared his thoughts about elevating female athletes, saying that hed always been abig supporter of the womens game. But having daughters who play sports his oldest, Natalia, plays volleyball was a big part of his desire to help push womens sports forward.

Just trying to enhance the womens game, not just in basketball but in volleyball and other sports, is extremely important. Anything I can do to help, Im gonna do.

He pointed to coaching his team at the Mamba Sports Academy, and telling the players and coaches that it was a group effort to win. Similarly, this is a joint effort to raise the womens game, he said.

Markazi also asked Bryant about his legacy, and whether he saw the Mamba Academy and youth sports playing a big role in how he was remembered.

Hopefully, he said, if we do it the right way, were known more for what we did after than what we did during.

I think you can have a lasting impact, he said. I mean winning championships, thats great. Building families, thats great. But when you can create stories and create moments and events and companies that can provide opportunities and inspire kids and create situations where people can be better, I think that has a lasting impact, more so than winning championships does.

More:
Kobe Bryant talked family and elevating female athletes in last interview with LA Times columnist - FOX 61

Recommendation and review posted by Bethany Smith

Appraiser earns highest professional status

Matt Hawk of Shackelford and Associates in Greenville has been awarded the Accredited Rural Appraiser (ARA) designation from the American Society of Farm Managers and Rural Appraisers.

Hawk earned the designation by meeting requirements in experience and education, in addition to passing written examination and abiding by the societys code of ethics.

Hawk joins a select 45 percent of the societys membership who have received the accredited status and currently maintain it through the societys continuing education program.

Accredited Rural Appraisers can ensure that an appraisal complies with regulations and requirements. They possess expertise exceeding nearly all state certification and licensing requirements.

In addition, an Accredited Rural Appraiser is connected to a national network of professional resource information.

The American Society of Farm Managers and Rural Appraisers is the largest professional society for rural property land experts, with more than 2,100 members in 31 chapters throughout the United States.

Dr. Craig Steffee joins Gastroenterology East

Gastroenterology East has announced the addition of its own in-house pathologist, Dr. Craig Steffee.

A North Carolina native, Steffee completed his undergraduate studies at Duke University as an Angier B. Duke Scholar with a B.S. in biology and genetics.

He obtained his M.D. at Wake Forest University Bowman Gray School of Medicine, where he was inducted into the Alpha Omega Alpha medical honor society.

He completed his internship and residency in Pathology at Bowman Gray School of Medicine/NC Baptist Hospital where he served as chief resident.

Steffee completed a fellowship in cytopathology at the ECU Brody School of Medicine and served on the faculty of the ECU Department of Pathology prior to entering private practice in 2000.

He is board certified in anatomic pathology, clinical pathology and cytopathology.

Steffee is skilled in surgical pathology and has been interpreting gastrointestinal biopsies in both hospital and outpatient gastroenterology endoscopy center settings in eastern North Carolina for more than 20 years.

Butler to focus on women investors at Milestone

Milestone Wealth has announced the expansion of its financial planning and wealth management services with an additional emphasis on women investors; especially those going through a life transition such as a job/career change, divorce, sale of a business, retirement or loss of a spouse or loved one. The firm long has specialized in providing financial services to medium and large-sized businesses, and is bringing its expertise to a vastly underserved market.

Belinda Butler, recently designated as a certified financial planner and moving into the role of associate wealth manager, will help lead this effort. A member of the Milestone Wealth team since 2016, Butler is suited to understand the needs of women investors and help them feel comfortable managing their financial lives, especially during and after times of significant change.

We want to help women make the best use of the resources you have to benefit your life, your family and the community, Butler said. Wealth is not just the money you have, it is your ability to use money to achieve the kind of life you want. The female portion of the market has always been underserved, and we are passionate about delivering sound financial guidance and advice in order to serve as an important catalyst and trusted partner that empowers them to take control of their financial lives.

Belinda is a tremendous asset to the Milestone Wealth team, said Dave Hunt, owner of Milestone Wealth. She will do an excellent job of connecting with women throughout our community and offering them the same high level of financial services that business owners and families have come to trust us with as we manage their wealth and investments.

Robinson recognized as 2020 Super Lawyer

Attorney Les Robinson of the Robinson Law Firm in Greenville has been recognized as a 2020 Super Lawyer.

This is the sixth consecutive year Robinson has received this honor. With more than 32 years of experience and having taken more than 3,500 cases to trial, Robinson has established himself as a seasoned trial-ready attorney representing his clients facing charges involving drugs and alcohol, violent crimes, wildlife offenses, domestic disputes and other criminal acts.

Each year, Super Lawyers rates lawyers from across the country to put together a list of the most elite attorneys in the United States. The criteria for the recognition includes 12 indicators of professional achievement and peer nominations. These indicators include verdicts/settlements, professional activity, honors/awards and experience. Through a rigorous process, the Super Lawyers recognition is only given to those attorneys with the most points earned during the evaluation.

The words Super Lawyers used to describe Robinson are experienced, skillful and relentless.

It is an honor to be recognized as one of the top attorneys in the country, Robinson said. I look forward to continuing to serve eastern North Carolina. Working diligently to prepare the best defense possible for my clients has always, and will always, remain my top priority.

Robinson was born and raised in Greenville. He graduated from East Carolina University and attended Campbell University School of Law where he received his Juris Doctorate degree in 1986.

After graduating from law school, he returned to Greenville where he entered into private practice in August 1986. Since that time, he has tried more than 3,500 bench and jury trials throughout eastern North Carolina.

Robinson repeatedly has been elected by his peers to leadership positions in local, district and state bar organizations. He served for nine years as the elected Bar Councilor representative to the North Carolina State Bar. As Bar Councilor, he served on numerous committees in the capacity as committee member, vice chairman and chairman. In addition, he is a frequent continuing legal education speaker for legal associations throughout the state. He has also given presentations for the North Carolina Advocates for Justice, North Carolina Bar Association, North Carolina Public Defenders and the North Carolina Institute of Government.

Keller Williams Realty hires new agents

Keller Williams Realty Points East has hired two new agents.

Tiki Jackson is a native of Boston, Mass., who has lived in the Greenville area for four months.

She is separated and has one child.

Jackson has been in real estate for the past 30 years.

Dan Jacobo is a native of Greenville and has lived in the area for 23 years.

He is single and in his spare time he enjoys soccer.

Jacobo has an associates degree in information technology.

He has been in real estate for one month.

Read the original post:
People in the News - Greenville Daily Reflector

Recommendation and review posted by Bethany Smith

The recent outbreak of the coronavirus has shown us that our global health system is only as strong as its weakest link.

The key to stemming the spread of such illnesses lies in bolstering connectivity and communication between health bodies and thats precisely the theme here at Arab Health 2020.

Artificial intelligence means medical bodies can link up their data and act quickly in a crisis.

"As emergency physicians and practitioners were often on the frontline. But Ill give you an example of how technology and AI may help outbreaks, not just Coronavirus, but for seasonal influenza," says Dr Jacques Kobersy, emergency medicine institute chair, Cleveland Hospital Abu Dhabi.

"When you have an organisation like WHO who are alerted to the fact that there is some new virus circulating, Artificial intelligence might give us the opportunity to flag that those unusual symptoms are occurring way before human clinicians and departments of health realize it. And help us get ahead of these sort of pandemics maybe a month or so ahead of time before they really fester."

55,000 attendees from 159 countries have touched down in Dubai to showcase and learn about the life-changing and groundbreaking technologies poised to transform healthcare as we know it.

Autonomous ambulances

Soon, AI could make autonomous ambulances that automatically arrive at a patients house as soon as somethings wrong.

"We call it a smart ambulance. The high-risk patient, they will start to wear wearable devices. Let's say something happened to that patient. These devices will start to send all the vital data to the system and the hospital. So the physician, he can monitor all the data and monitor the patient 24 hour," says Dr Rashid al Hashimi - youth council member, UAE ministry of health (mohap).

In the future, the ambulance will be auto-drive. So it will go directly to the patient. While they are moving all these signals will be green for them.

When the patient enters the ambulance, there will be some high-resolution cameras. They will detect the patient's face and will give all the data which is very important for the rescuers to help the patient.

While they are going to the hospital, there will be like a virtual doctor inside the ambulance.

AI implants

AI is already powering implants that can monitor patients vitals around the clock.

"We can put devices under the skin and telemonitor heart patients even at home. We have put this device on 30 patients," says Dr Noor al Muhairi, head of medical services, hospital dept (mohap).

"One of them was in London. And we saw that we have an abnormality in his heart. And we called them directly and told him, go to the nearest hospital and this saved him."

And unprecedented advancements in stem-cell research mean damaged heart cells can now be regrown.

"In treatment, we collaborated with Osaka University, where they have done a study on stem cells that have been generated to cardiac cells. You can bring stem cells to make the heart cells regenerate," says Dr Muhairi.

"So this is one of the latest technology in heart treatment and in collaboration with Japan, we are going to do a clinical study here in the Ministry of Health."

Analysing wounds

Meanwhile, image analysis of wounds using machine learning can now prevent amputations caused by diseases like diabetes.

"This machine is checking the healing process for the diabetic foot. It will give us the results within 30 seconds. We are just scanning for the wound.2

"There is information going back 15 years in this machine. So it will check with other types of wound and it will analyze for us exactly the problem. We can prevent amputations from the complication of diabetes," says Dr Halima el Shehhi, the emergency department unit manager at the ministry of health and prevention, UAE.

Whether it's artificial intelligence, new equipment, new abilities to analyze patients and treat them, things that we could only imagine a few years ago now have come to fruition.

Soon the days of treating illnesses after they occur will give way to an age of truly preventative healthcare.

Original post:
AI is transforming healthcare as we know it: Arab Health 2020 - Euronews

Recommendation and review posted by Bethany Smith

BOTHELL, Wash. and TOKYO, Feb. 10, 2020 /PRNewswire/ --Seattle Genetics, Inc.(Nasdaq: SGEN) and Astellas Pharma Inc.(TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy. Forty-five patients were treated with the combination of PADCEV (enfortumab vedotin-ejfv) and pembrolizumab and were evaluated for safety and efficacy. After a median follow-up of 11.5 months, the study results continue to meet outcome measures for safety and demonstrate encouraging clinical activity for this platinum-free combination in a first-line setting. Updated results will be presented during an oral session on Friday, February 14 at the 2020 Genitourinary Cancers Symposium in San Francisco (Abstract #441). Initial results from the study were presented at the European Society of Medical Oncology Congress in September 2019.

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.1,2

"Cisplatin-basedchemotherapy is the standard treatment for first-line advanced urothelial cancer; however, it isn't an option for many patients,"said Jonathan E. Rosenberg, M.D., Medical Oncologist and Chief, Genitourinary Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York."I'm encouraged by these interim results, including a median progression-free survival of a year for patients who received the platinum-free combination of PADCEV and pembrolizumab in the first-line setting."

In the study, 58 percent (26/45) of patients had a treatment-related adverse event greater than or equal to Grade 3: increase in lipase (18 percent; 8/45), rash (13 percent; 6/45), hyperglycemia (13 percent; 6/45) and peripheral neuropathy (4 percent; 2/45); these rates were similar to those observed with PADCEV monotherapy.3Eighteen percent (8/45) of patients had treatment-related immune-mediated adverse events of clinical interest greater than or equal to Grade 3 that required the use of systemic steroids (arthralgia, dermatitis bullous, pneumonitis, lipase increased, rash erythematous, rash maculo-papular, tubulointerstitial nephritis, myasthenia gravis). None of the adverse events of clinical interest were Grade 5 events. Six patients (13 percent) discontinued treatment due to treatment-related adverse events, most commonly peripheral sensory neuropathy. As previously reported, there was one death deemed to be treatment-related by the investigator attributed to multiple organ dysfunction syndrome.

The data demonstrated the combination of PADCEV plus pembrolizumab shrank tumors in the majority of patients, resulting in a confirmed objective response rate (ORR) of 73.3 percent (33/45; 95% Confidence Interval (CI): 58.1, 85.4) after a median follow-up of 11.5 months (range,0.7 to 19.2). Responses included 15.6 percent (7/45) of patients who had a complete response (CR)and 57.8 percent (26/45) of patients who had a partial response. Median duration of response has not yet been reached (range 1.2 to 12.9+ months). Eighteen (55%) of 33 responses were ongoing at the time of analysis, with 83.9% of responses lasting at least 6 months and 53.7% of responses lasting at least 12 months (Kaplan-Meier estimate).The median progression-free survival was 12.3 months (95% CI: 7.98, -) and the 12-month overall survival (OS) rate was 81.6 percent (95% CI: 62 to 91.8 percent); median OS has not been reached.

"These updated data are encouraging and provide support for the recently initiated phase 3 trial EV-302 that includes an arm evaluating PADCEV in this platinum-free combination in the first-line setting," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.

"These additional results support continued evaluation of PADCEV in combination with other agents and at earlier stages of treatment for patients withurothelial cancer," said Andrew Krivoshik, M.D., Ph.D., Senior Vice President and Oncology Therapeutic Area Head at Astellas.

About the EV-103 TrialEV-103 is an ongoing, multi-cohort, open-label, multicenter phase 1b/2 trial of PADCEV alone or in combination, evaluating safety, tolerability and efficacy in muscle invasive, locally advanced and first- and second-line metastatic urothelial cancer.

The dose-escalation cohort and expansion cohort A include locally advanced or metastatic urothelial cancer patients who are ineligible for cisplatin-based chemotherapy. Patients were dosed in a 21-day cycle, receiving an intravenous (IV) infusion of enfortumab vedotin on Days 1 and 8 and pembrolizumab on Day 1. At the time of this initial analysis, 45 patients (5 from the dose-escalation cohort and 40 from the dose-expansion cohort A) with locally advanced and/or metastatic urothelial cancer had been treated with enfortumab vedotin (1.25 mg/kg) plus pembrolizumab in the first-line setting.

The primary outcome measure of the cohorts included in this analysis is safety. Key secondary objectives related to efficacy include objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression free survival (PFS) and overall survival (OS). DoR,PFS and OS are not yet mature.

Additional cohorts in the EV-103 study will evaluate enfortumab vedotin:

More information about PADCEV clinical trials can be found at clinicaltrials.gov.

About Bladder and Urothelial CancerIt is estimated that approximately 81,000 people in the U.S. will be diagnosed with bladder cancer in 2020.5 Urothelial cancer accounts for 90 percent of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.6 Globally, approximately 549,000 people were diagnosed with bladder cancer in 2018, and there were approximately 200,000 deaths worldwide.7

The recommended first-line treatment for patients with advanced urothelial cancer is a cisplatin-based chemotherapy. For patients who are ineligible for cisplatin, such as people with kidney impairment, a carboplatin-based regimen is recommended. However, fewer than half of patients respond to carboplatin-based regimens and outcomes are typically poorer compared to cisplatin-based regimens.8

About PADCEV PADCEV (enfortumabvedotin-ejfv) was approved by the U.S. Food and Drug Administration (FDA) in December 2019 and is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting. PADCEV was approved under the FDA's Accelerated Approval Program based on tumor response rate. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.9

PADCEV is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.2,9Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).9PADCEV is co-developed by Astellas and Seattle Genetics.

Important Safety Information

Warnings and Precautions

Adverse ReactionsSerious adverse reactions occurred in 46% of patients treated with PADCEV. The most common serious adverse reactions (3%) were urinary tract infection (6%), cellulitis (5%), febrile neutropenia (4%), diarrhea (4%), sepsis (3%), acute kidney injury (3%), dyspnea (3%), and rash (3%). Fatal adverse reactions occurred in 3.2% of patients, including acute respiratory failure, aspiration pneumonia, cardiac disorder, and sepsis (each 0.8%).

Adverse reactions leading to discontinuation occurred in 16% of patients; the most common adverse reaction leading to discontinuation was peripheral neuropathy (6%). Adverse reactions leading to dose interruption occurred in 64% of patients; the most common adverse reactions leading to dose interruption were peripheral neuropathy (18%), rash (9%) and fatigue (6%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common adverse reactions leading to dose reduction were peripheral neuropathy (12%), rash (6%) and fatigue (4%).

The most common adverse reactions (20%) were fatigue (56%), peripheral neuropathy (56%), decreased appetite (52%), rash (52%), alopecia (50%), nausea (45%), dysgeusia (42%), diarrhea (42%), dry eye (40%), pruritus (26%) and dry skin (26%). The most common Grade 3 adverse reactions (5%) were rash (13%), diarrhea (6%) and fatigue (6%).

Lab AbnormalitiesIn one clinical trial, Grade 3-4 laboratory abnormalities reported in 5% were: lymphocytes decreased, hemoglobin decreased, phosphate decreased, lipase increased, sodium decreased, glucose increased, urate increased, neutrophils decreased.

Drug Interactions

Specific Populations

For more information, please see the full Prescribing Information for PADCEV here.

About Seattle GeneticsSeattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people's lives. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit https://www.seattlegenetics.comand follow @SeattleGenetics on Twitter.

About AstellasAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en.

About the Astellas and Seattle Genetics CollaborationSeattle Genetics and Astellas are co-developing enfortumab vedotin-ejfv under a collaboration that was entered into in 2007 and expanded in 2009. Under the collaboration, the companies are sharing costs and profits on a 50:50 basis worldwide.

Seattle Genetics Forward-Looking StatementsCertain statements made in this press release are forward looking, such as those, among others, relating to the EV-103 and EV-302 clinical trials; clinical development plans relating to enfortumab vedotin; the therapeutic potential of enfortumab vedotin; and its possible safety, efficacy, and therapeutic uses, including in the first-line setting. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the possibility that ongoing and subsequent clinical trials of enfortumab vedotin may fail to establish sufficient efficacy; that adverse events or safety signals may occur and that adverse regulatory actions or other setbacks could occur as enfortumab vedotin advances in clinical trials even after promising results in earlier clinical trials. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption "Risk Factors" included in the company's Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Astellas Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

1 PADCEV [package insert]. Northbrook, IL: Astellas, Inc.2 Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.3 Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2019;37(29):2592-600.4 ClinicalTrials.gov. A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103). https://clinicaltrials.gov/ct2/show/NCT03288545.5 American Cancer Society. Cancer Facts & Figures 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed 01-23-2020.6National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 05-01-2019.7International Agency for Research on Cancer. Cancer Tomorrow: Bladder. http://gco.iarc.fr/tomorrow. 8 National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 4; July 10, 2019. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.9 PADCEV [package insert]. Northbrook, IL: Astellas, Inc.

SOURCE Astellas

http://www.seattlegenetics.com

View original post here:
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV (enfortumab vedotin-ejfv) in Combination with Immune Therapy...

Recommendation and review posted by Bethany Smith

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

To know Untapped Opportunities in the MarketCLICK HERE NOW

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Get Discount on Latest Report @CLICK HERE NOW

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

View original post here:
Regenerative Medicine Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2025 - Jewish Life News

Recommendation and review posted by Bethany Smith

RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor Therapeutics subsidiary today announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101. NAN-101 is a gene therapy that aims to activate protein phosphatase inhibitor 1 (I-1c) to inhibit the activity of protein phosphatase 1 (PP1), a substance that plays an important role in the development of heart failure.

Congestive heart failure (CHF) is a condition in which the heart is unable to supply sufficient blood and oxygen to the body and can result from conditions that weaken the heart muscle, cause stiffening of the heart muscles, or increase oxygen demand by the body tissues beyond the hearts capability.

"Dosing the first patient using gene therapy to target I-1c to improve heart function is a tremendous milestone not only for the AskBio and NanoCor teams but, more importantly, for patients whose quality of life is negatively affected by CHF, said Jude Samulski, PhD, Chief Scientific Officer and co-founder of AskBio. We initially developed this gene therapy as treatment for late-stage Duchenne muscular dystrophy patients who typically die from cardiomyopathy. Following preclinical studies, we observed that heart function improved, which led us to investigate treatment for all types of heart failure.

Were excited to be involved in this novel approach for patients with Class III heart failure, said Timothy Henry, MD, FACC, MSCAI, Lindner Family Distinguished Chair in Clinical Research and Medical Director of The Carl and Edyth Lindner Center for Research at The Christ Hospital in Cincinnati, Ohio, and principal investigator for the study. These patients currently have no other options besides transplant and left ventricular assist devices (LVAD). Today, we started to explore the potential of gene therapy to change their outcomes.

Heart disease is the leading cause of death worldwide, with CHF affecting an estimated 1% of the Western world, including over six million Americans. There is no cure, and medications and surgical treatments only seek to relieve symptoms and slow further damage.

Research by many investigators around the world has been trying to understand what exactly goes wrong in the heart and weakens its pumping activity until it finally fails, said Evangelia (Litsa) Kranias, PhD, FAHA, Hanna Professor, Distinguished University Research Professor and Director of Cardiovascular Biology at the University of Cincinnati College of Medicine. The aim has been to identify potential therapeutic targets to restore function or prevent further deterioration of the failing heart. Along these lines, research on the role of I-1c started over two decades ago, and it moved from the lab bench to small and large animal models of heart failure. The therapeutic benefits at all levels were impressive. It is thrilling to see I-1c moving into clinical trials with the hope that it also improves heart function in patients with CHF.

About the NAN-101 Clinical Trial NAN-CS101 is a Phase 1 open-label, dose-escalation trial of NAN-101 in subjects with NYHA Class III heart failure. NAN-101 is administered directly to the heart via an intracoronary infusion by cardiac catheterization in a process similar to coronary angioplasty, commonly used to deliver treatments such as stem cells to patients with heart disease. The primary objective of the study is to assess the safety of NAN-101 for the treatment of NYHA Class III heart failure, as well as assess the impact of this treatment on patient health as measured by changes in exercise capacity, heart function and other factors including quality of life.

AskBio is actively enrolling patients with NYHA Class III heart failure to assess three doses of NAN-101. Please refer to clinicaltrials.gov for additional clinical trial information.

Would you like to receive our AskFirst patient engagement program newsletter? Sign up at https://www.askbio.com/patient-advocacy.

About The Christ Hospital Health Network The Christ Hospital Health Network is an acute care hospital located in Mt. Auburn with six ambulatory centers and dozens of offices conveniently located throughout the region. More than 1,200 talented physicians and 6,100 dedicated employees support the Network. Its mission is to improve the health of the community and to create patient value by providing exceptional outcomes, the finest experiences, all in an affordable way. The Network has been recognized by Forbes Magazine as the 24th best large employer in the nation in the magazines Americas 500 Best Large Employers listing and by National Consumer Research as the regions Most Preferred Hospital for more than 22 consecutive years. The Network is dedicated to transforming care by delivering integrated, personalized healthcare through its comprehensive, multi-specialty physician network. The Christ Hospital is among only eight percent of hospitals in the nation to be awarded Magnet recognition for nursing excellence and among the top five percent of hospitals in the country for patient satisfaction. For more than 125 years, The Christ Hospital has provided compassionate care to those it serves.

About AskBioFounded in 2001, Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held, clinical-stage gene therapy company dedicated to improving the lives of children and adults with genetic disorders. AskBios gene therapy platform includes an industry-leading proprietary cell line manufacturing process called Pro10 and an extensive AAV capsid and promoter library. Based in Research Triangle Park, North Carolina, the company has generated hundreds of proprietary third-generation AAV capsids and promoters, several of which have entered clinical testing. An early innovator in the space, the company holds more than 500 patents in areas such as AAV production and chimeric and self-complementary capsids. AskBio maintains a portfolio of clinical programs across a range of neurodegenerative and neuromuscular indications with a current clinical pipeline that includes therapeutics for Pompe disease, limb-girdle muscular dystrophy type 2i/R9 and congestive heart failure, as well as out-licensed clinical indications for hemophilia (Chatham Therapeutics acquired by Takeda) and Duchenne muscular dystrophy (Bamboo Therapeutics acquired by Pfizer). For more information, visit https://www.askbio.com or follow us on LinkedIn.

See the original post:
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure - BioSpace

Recommendation and review posted by Bethany Smith

Press Release

Gosselies, Belgium, 11February 2020, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, announces that the Company will today present at the Annual Meeting of the Orthopaedic Research Society (ORS), in Phoenix (Arizona), USA.

The Annual ORS Meeting is the yearly summit organised by the international Orthopaedic Research Society, gathering scientists, clinicians and entrepreneurs to advance musculoskeletal research and orthopaedic care. In the oral presentation, Bone Therapeutics will highlight additional preclinical in vitro and in vivo results demonstrating the potent osteogenic properties of its allogeneic bone-forming cell therapy platform, ALLOB, to promote bone-formation and improve fracture healing in relevant models.

ALLOB is the Companys allogeneic product that consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors, and is manufactured through a proprietary, scalable production process. ALLOB successfully completed two Phase II studies in two indications and the Company has started the CTA submission procedure with the regulatory authorities in Europe to start the PhaseIIb clinical trial in patients with difficult-to-heal tibial fractures.

Presentation Details:

Title: ALLOB, A Ready-to-use and Injectable Cryopreserved Allogenic Cell Therapy Product Derived from Bone Marrow Mesenchymal Stem Cells, Displays Potent Osteoinductive and Osteogenic Properties, Leading to Enhanced Bone Fracture HealingSpeaker: Sandra Pietri, PhD Associate Director R&D, Bone TherapeuticsSession: Podium Session 58 Bone Cell Signaling and TreatmentsDate: Tuesday, 11 February 2020Time: 8:00am 9:00am MST (4pm 5 pm CET)Location: Room West 301D, Phoenix Convention Center, Phoenix, Arizona, USA

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) to start the pivotal Phase III program has been submitted to the regulatory authorities in Europe and the trial is expected to start in Q1 2020.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the promising Phase IIa efficacy and safety results for ALLOB, the Company has started the CTA submission procedure with the regulatory authorities in Europe to start the Phase IIb clinical trial with ALLOB in patients with difficult-to-heal fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

Story continues

Contacts

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Consilium Strategic CommunicationsMarieke VermeerschTel: +44 (0) 20 3709 5701bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

See original here:
Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the Orthopaedic Research...

Recommendation and review posted by Bethany Smith

'This is the beginning of my new life'

I thought my cancer diagnosis was a death sentence, said Lynnette Williams-Briggs, 60, of Seaford, Delaware, who was diagnosed with advanced B-cell lymphoma in 2018.

Briggs cancer is now in complete remission thanks to successful chimeric antigen receptor CAR-T cell therapy she received in August atChristianaCaresHelen F. Graham Cancer Center & Research InstitutesBone Marrow and Stem Cell Transplant Program.

I can breathe again. This is the beginning of my new life, Williams-Briggs said following the treatment that restored her hope for a second chance at life.

She was the first patient to receive CAR-T cell therapy in Delaware. A second patient was treated in December 2019, and doctors are preparing several more patients for CAR-T cell transplants in coming weeks.

The U.S. Food and Drug Administration has approved CAR-T cell therapy to treat patients like Williams-Briggs with highly resistant, B-cell blood cancers, for whom other available options have failed.

CAR-T cell therapy is only available at select cancer centers with specialized expertise in cellular therapies that are recognized for quality by the Foundation for the Accreditation of Cellular Therapy.

The Graham Cancer Centers Bone Marrow and Stem Cell Transplant Program is the only one in Delaware that is certified to treat adult patients with advanced B-cell lymphomas and children and young adults (to age 25) with acute lymphoblastic leukemia, using an FDA-approved drug.

CAR-T cell therapy is highly personalized medicine that attempts to use the bodys natural defenses to fight against cancer. The transplant team extracts millions of T cells, from the patients bloodstream, using a specialized blood filtration process called leukapheresis. The collected T cells are flash-frozen and sent to a lab for reprogramming, and then later infused back into the patient using a process similar to a blood transfusion.

The therapy is considered a living drug with potential benefits that could last for years.

When we first met Ms. Williams-Briggs, her cancer had progressed rapidly despite a third round of chemotherapy, so we knew we had to move quickly, said Graham Cancer Center Hematologist Peter Abdelmessieh, D.O. He worked closely with the bone marrow/stem cell transplant team and Graham Cancer Center leadership over the course of just eight months to develop the CAR-T cell therapy program.

It was truly a team effort to bring CAR-T cell therapy to our community so quickly, Dr. Abdelmessieh said.

CAR-T cell therapy has been extremely effective for many patients like Williams-Briggs, whose PET scan at 90 days confirmed her remission.

The supercharged T cells Williams-Briggs received were genetically modified in the lab to sprout new surface tools that improve their ability to recognize, latch onto and destroy other cells (including cancer cells) that express a specific antigen called CD19. These reprogrammed cells continue to multiply in the body after treatment, remaining on guard to seek and destroy any new cancers that might develop.

With continued success in increasing numbers of patients, it is conceivable that in the not too distant future, CAR-T cell therapy could become the new standard of care, replacing chemotherapy and stem cell transplants for many cancers, Dr. Abdelmessieh said.

The extended recovery period for CAR-T cell therapy is generally two to three months. After the infusion, patients may spend up to three weeks in the hospital to monitor treatment response and any side effects.

During the first 30 days after leaving the hospital, patients are required to remain close to the treatment center for regular follow-up care.

The ability to offer potentially life-saving CAR-T cell therapy is one more reason our patients need not travel further than the Graham Cancer Center for state-of-the-science cancer treatment, said Nicholas J. Petrelli, M.D., Bank of America medical director of the Helen F. Graham Cancer Center & Research Institute.

The Bone Marrow and Stem Cell Transplant Program is an outstanding example of how well our clinical teams work together to drive innovation in patient care.

Although patients normally do not experience the side effects associated with chemotherapy, such as nausea, vomiting or hair loss, CAR-T cell therapy is not without risks. A common side effect, which Williams-Briggs also experienced, is cytokine release syndrome. This is an inflammatory condition that causes flu-like symptoms that may be mild or severe.

The transplant team responded quickly to manage her symptoms while she received expert care on the Bone Marrow Transplant and Oncology unit at Christiana Hospital.

From the moment I first met with my transplant team, I felt like I was part of one big loving family that extended beyond my own loved ones, Williams-Briggs said.

Dr. Abdelmessieh and my ChristianaCare family gave me hope to keep fighting when I really didnt think I would make it. I would have driven anywhere to get life-saving treatment, but I am thankful that I did not have to. I found my miracle closer to home.

Read the rest here:
First CAR-T cell cancer therapy patient in Delaware - Dover Post

Recommendation and review posted by Bethany Smith

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart.

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction.

Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one, Dr Ban said.

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

In the study, the hiPSC-CMs were injected directly into the border zone of the rats heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart.

We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist, Dr Ban added.

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

Read more:
First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair - QS WOW News

Recommendation and review posted by Bethany Smith

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company recently held a high level meeting with the U.S. Food and Drug Administration (FDA) to discuss potential NurOwn regulatory pathways for approval in ALS. Repeated intrathecal administration of NurOwn (autologous MSC-NTF cells) is currently being evaluated in a fully enrolled Phase 3 pivotal trial in ALS (NCT03280056).

In the planned meeting with senior Center for Biologics Evaluation and Research (CBER) leadership and several leading U.S. ALS experts, the FDA confirmed that the fully enrolled Phase 3 ALS trial is collecting relevant data critical to the assessment of NurOwn efficacy. The FDA indicated that they will look at the "totality of the evidence" in the expected Phase 3 clinical trial data. Furthermore, based on their detailed data assessment, they are committed to work collaboratively with BrainStorm to identify a regulatory pathway forward, including opportunities to expedite statistical review of data from the Phase 3 trial.

Both the FDA and BrainStorm acknowledged the urgent unmet need and the shared goal of moving much needed therapies for ALS forward as quickly as possible.

This is a key turning point in ourworktowardprovidingALSpatientswith a potential new therapy,said ChaimLebovits, President and CEO ofBrainStorm. We commend the FDA foritscommitmentto the ALS communityandtofacilitating the development, and we ultimately hope, the approvalofNurOwn.The entire BrainStorm team is grateful for the ongoing and conscientious collaboration in the quest to beat ALS.

Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, stated, The entire team at BrainStorm has collectively worked to ensure that we conduct the finest, science-based clinical trials. We had the opportunity to communicate with Senior Leadership at the FDA and discuss how we can work together to navigate the approval process forward along a novel pathway. We appreciate their willingness and receptiveness to consider innovative approaches as we all seek to better serve the urgent unmet medical needs of the ALS community.

Brian Wallach, Co-Founder of I AM ALS stated: There is nothing more important to those living with ALS than having access to therapies that effectively combat this fatal disease. We have been working with BrainStorm for months now because we believe that NurOwn is a potentially transformative therapy in this fight. We were privileged to represent the patient voice at this meeting and are truly grateful to the company and the FDA for this critical agreement. This is a truly important moment of hope and we look forward to seeing both the Phase III data and the hopeful approval of NurOwn as soon as is possible.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. BrainStorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Or

Katie Gallagher | Account Director, PR and MarketingLaVoieHealthScience Strategic CommunicationsO: 617-374-8800 x109M: 617-792-3937kgallagher@lavoiehealthscience.com

See the original post:
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn Regulatory Pathway for Approval in ALS - Yahoo Finance

Recommendation and review posted by Bethany Smith

Methionine is an amino acid found in meat, eggs, and dairy. Its absorbed by T-cells that are part of our immune system. Those cells are also believed to be the immune cells that attack our myelin, creating the nerve damage that results in multiple sclerosis.

In this study, mice eating less methionine had a reduced number of a certain type of T-cell, which led to a delay in disease onset and progression. The researchers believe reducing methionine intake can actually dampen the immune cells that cause disease, leading to better outcomes.

Changing a persons diet to reduce the amount of methionine (amino acid found in food) could delay the development and progression of inflammatory and autoimmune disorders, including multiple sclerosis (MS).

That finding was described in the study Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming, published recently in the journal Cell Metabolism.

Click here to read the full story.

***

Unlike hematopoietic stem cell transplants, in which stem cells are removed from a patients bone marrow and later infused back into the bloodstream, mesenchymal stem cell transplants (MSCT) collect those stem cells from the patients spinal column and return them there. This study concludes that MSCT is safe and that cells delivered into the spinal cord produced a significantly slower disease progression rate than did cells delivered into the bloodstream.

Transplanting patients ownmesenchymal stem cellsis a safe therapeutic approach and can delay disease progression in people with MS, a meta-analysis review shows.

The study also showed that cells transplanted to the spinal cord (intrathecal injection) were associated with significantly slower disease progression rates, compared to cells delivered into the bloodstream.

Click here to read the full story.

***

Why do neurologists often use spinal taps when determining whether someone has MS? This study provides one of the reasons.

People with MS have a more diverse set of immune cells in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, but no such diversity is seen in their blood, a study reports. Instead, MS causes changes in the activation of immune cells in the blood.

The distinct set of immune cells in MS patients CSF shows enrichment of pro-inflammatory cells that promote disease severity in MS mouse models.

Click here to read the full story.

***

Heres encouraging news about a possible treatment that can lower the number of brain lesions in someone with MS. Keep in mind this is only a Phase 2 trial. A Phase 3 trial isnt expected until later this year. However, a news release from research sponsor Sanofisays, This molecule may be the first B-cell-targeted MS therapy that not only inhibits the peripheral immune system, but also crosses the blood-brain barrier to suppress immune cells that have migrated into the brain.

The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint a significant reduction in the number of new lesions visible on a brain imaging scan in a Phase 2 trial in people with MS, study results show.

SAR442168, formerly known as PRN2246, is an oral, small molecule being co-developed by Principia Biopharmaand Sanofi Genzyme. It works by inhibiting Brutons tyrosine kinase (BTK), a protein important for the proliferation of immune cells, particularly B-cells. By blocking BTK, it is expected that SAR442168 can reduce inflammation that damages the nervous system in people with MS.

Click here to read the full story.

Did you know that some of my columns from The MS Wire are now available as audio briefings? You can listen to them here.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

Read more here:
MS News that Caught My Eye Last Week: Methionine, MSCT, Spinal... - Multiple Sclerosis News Today

Recommendation and review posted by Bethany Smith

When actor Danny Thomas opened St. Jude Children's Research Hospital in 1962, the survival rate for childhood cancer was just 20 percent. Today, that rate is 80 percent, thanks to medical advancements and research breakthroughs -- including those made by the doctors at St. Jude.

St. Jude's work treating children with cancer from across the world at no charge to their families is well-known, but doctors at the hospital are also conducting more clinical trials for cancer than any other children's hospital. The St. Jude Children's Research Hospital -- Washington University Pediatric Cancer Genome Project has resulted in groundbreaking discoveries about several childhood cancers, and in April, the St. Jude research team announced that they had developed a gene therapy that can cure infants born withX-linked severe combined immunodeficiency, commonly known as "bubble boy disease."

In addition, St. Jude leads the Childhood Cancer Survivor Study, which includes more than 30 institutions across North America and more than 20,000 childhood cancer survivors. All of the research that St. Jude's doctors do, and all of the discoveries they make, are shared freely with doctors and scientists worldwide -- an important contribution to not only the treatment of childhood cancers but, hopefully, the discovery of cures.

"The research facilities here are fantastic. Like, when you donate to St. Jude, you're not just donating to help the kids and their families, you're donating for this tremendous amount of research that's going into save more lives," shared King Calaway during the 2020 Country Cares for St. Jude Kids seminar in Memphis, Tenn., in mid-January. "It's fantastic ... And the fact that it's openly shared among other researches all around the world ... That's incredible."

When the rising country band and other artists visited St. Jude during the Country Cares seminar, they were offered a look inside the hospital's research lab. Johnny McGuire called the experience "really cool," and marveled at how the organization shares all of their discoveries, while Jackson Michelson recalled to The Boot his conversation with a doctor from the UK who had planned to work at St. Jude for one year but has now been at the hospital for a decade.

"I thought it was gonna be a cry-fest for me, but I left so inspired by what I saw, and the real, hard data of support, of success," admitted Brett Kissel. "It's an incredible facility ... This is an establishment that works ... and it's getting better with every year."

Independent artist Abbey Cone, too, was blown away by the doctors she met in the research lab, and the other St. Jude employees she met during her time at the hospital. "Every person I talked to today ... you could literally see the passion they have for their job and St. Jude as an organization," she reflected.

On Feb. 6-7, more than a dozen country radio stations owned by Townsquare Media, The Boot's parent company, will hold their 2020 Country Cares radiothons to raise money for St. Jude Children's Research Hospital. In the past six years, these stations have raised more than $9.2 million, and even more money has come from additional TSM stations that hold radiothons later in the year. To join the fight against childhood cancer and become a Partner in Hope, visit St. Jude's official website.

Country Cares Through the Years: See the Stars With St. Jude Patients

Read the rest here:
In St. Jude's Research Labs, 'You Can Literally See the Passion' for Finding Cures - The Boot

Recommendation and review posted by Bethany Smith